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Genome-wide association studies (GWAS) have identified hundreds of thousands of
variants associated with a broad range of complex traits. However, the biological mechanisms
underlying these associations remain largely unknown. Transcriptome-wide association
studies (TWAS) are a gene-based method which can provide insight into these mechanisms
by leveraging the regulatory influence of variants on gene expression in order to infer the
effect of genetically-regulated gene expression on a complex trait. In the first chapter of
this dissertation, I discuss the current TWAS methods and assumptions that they impose
on the estimation of SNP-gene effect sizes. I further highlight key characteristics of TWAS
approaches and conclude with challenges in and solutions for interpreting TWAS results,
and consider future directions for methodological development and opportunities for the
application of TWAS methods in ongoing genomic studies.
In Chapter 2, I perform a large-scale TWAS of hematological phenotypes in the Genetic
Epidemiology Research on Aging cohort and reveal complexities in TWAS fine-mapping. I
highlight regions of the genome which contain multiple TWAS signals; I show how numer-
ous factors, including correlation among predicted expression across genes, shared variants
contributing to predictive models of genes, and linkage disequilibrium patterns among the
variants, impact TWAS interpretation. Integrating marginal TWAS results with conditional
TWAS, TWAS meta-analyses, previous knowledge from the most comprehensive GWAS
of hematological phenotypes, fine-mapping approaches, and studies of biological function
iii
further inform the process of distinguishing between causal and spurious signals within a
genomic region.
To aid TWAS interpretation and efficiently integrate TWAS, GWAS, and fine-mapping
results together, in Chapter 3, I develop an R Shiny application called LocusXcanR. This
application facilitates TWAS interpretation, can be extended to include additional ’omics data,
and highlights R Shiny’s effectiveness at presenting results in an approachable, interactive,
and visual format.
In Chapter 4, I apply the TWAS framework to analyze metabolites in a metabolome-wide
association study of European and African Americans in the Atherosclerosis Risk in Com-
munities Study. Using hematological phenotypes, I highlight the challenges in replicating
observed associations in predicted metabolites. However, improving model performance may
still support the potential effectiveness of the TWAS framework to other ’omics data.
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CHAPTER 1: LITERATURE REVIEW
1.1 Introduction
Genetic variation between individuals can cause differences in phenotypes, including the
differential emergence of complex diseases and disease processes. Genome-wide association
studies (GWAS) are a method used to uncover the associations between genetic variation
and phenotype, and they have identified thousands of genetic loci containing phenotype-
associated variants. While GWAS will certainly continue to identify phenotype-associated
variants and loci, these studies suffer from many challenges (Tam et al., 2019).
First, GWAS studies typically conduct single variant tests to interrogate the genome, and
in such cases, they must rely on increasingly large sample sizes to counteract the presence
of a substantial multiple testing burden, detect small or even moderate effect sizes, and make
meaningful inferences (Spencer et al., 2009). Additionally, the genome-wide significant asso-
ciations that have been identified across a wide range of phenotypes generally only account
for a modest proportion of disease risk (Manolio et al., 2009). Importantly, despite the large
number of disease susceptibility loci that have been identified by GWAS, these associations
do not commonly result in conclusive findings on the genetic factors contributing to complex
traits. Indeed, the functional relevance of discovered loci remains largely unclear. This is
due in part to the fact that establishing a causal link between trait-associated variants and a
functional, biologically relevant gene can be an onerous endeavour. In the original reports of
GWAS results, the assignment of a gene to a trait-associated variant typically only depends
on the variant’s 1-dimensional physical proximity to the gene, and does not generally eluci-
date a functional connection.
1
Establishing this functional connection between genetic variability and disease risk re-
mains a challenge in advancing our biological understanding of the mechanisms underlying
these relationships. Gene-based approaches to this problem have been developed alongside
the volume of transcriptomic data that are being generated by large genomic consortia, includ-
ing the Encyclopedia of DNA Elements (ENCODE 2012), the Genotype-Tissue Expression
Project (GTEx 2013; 2020), and others (Lappalainen et al., 2013; Battle et al., 2014; Ra-
masamy et al., 2014). It is understood that, for a wide range of disease phenotypes, a large
portion of their variability in disease risk can be explained by genetic variants that regulate
the expression levels of genes (Nicolae et al., 2010; Gamazon et al., 2010; Davis et al., 2013;
Gamazon et al., 2013; Gusev et al., 2014). Genetic variants may also be linked to their plausi-
ble function by other factors such as microRNA regulation and chromatin conformation quan-
titative trait loci (QTLs); however, these effects are often ultimately mediated through gene
expression as well. One of the first gene-based methods to fully leverage these transcriptome
data, proposed by Gamazon et al. (2015), employs a single nucleotide polymorphism (SNP)
aggregation technique that integrates information regarding the SNP-regulated expression of
a gene in order to pinpoint trait-identified loci. This method along with others (discussed in
more detail in the following sections of this chapter) are referred to as transcriptome-wide
association studies (TWAS). Since these methods utilize the gene as the functionally relevant
unit of analysis, they provide advantages beyond GWAS, which include reducing the multiple
testing burden, potentially identifying the causal pathway between genetic variation and phe-
notype, discovering novel loci missed by GWAS, and generally improving our understanding
of the genetic basis of complex traits.
In the following sections of this chapter, we discuss these TWAS methods in detail, show
where we have seen TWAS contribute to improved understanding of complex diseases (such
as breast cancer and schizophrenia), and address some of the challenges that arise when
interpreting TWAS results.
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1.2 Transcriptome-wide Association Studies
Transcriptome-wide association studies (TWAS) are a gene-based statistical method
which integrate data from GWAS and gene expression studies. Through a process of model
training in a gene expression reference panel, predicting gene expression in an analytical co-
hort, and associating predicted gene expression with a phenotype, TWAS can help us to better
understand the molecular/biological and causal mechanisms that underlie the variant-trait as-
sociations previously identified by GWAS. Many statistical methods have been proposed over
the past several years, and although the objective of each method is essentially the same, they
rely on different modeling assumptions. In the following subsections, we highlight the differ-
ences in these assumptions, in particular emphasizing frequentist versus Bayesian approaches
to model training. We further discuss key features of the methods regarding whether they are
designed to use individual-level and/or summary-based data and whether they are capable of
performing single tissue and/or multiple tissue analysis. We conclude by addressing some
of the challenges that arise in interpreting TWAS results and discuss future directions for
methodological development as well as opportunities for the application of TWAS methods in
ongoing genomic studies.
1.2.1 Methodological Differences in Modeling Assumptions
Since many large genetic cohorts do not contain gene expression data, and may only have
access to individual level genotype data or summary statistics, TWAS methods begin with
training models in a gene expression reference panel which contains both gene expression
and genotype data. Weights from the trained models are then used to predict gene expression
in an analytical sample containing genotype data. Finally, the predicted expression values
are associated with the phenotype in the analytical sample. Thus, each modeling approach
utilizes a basic framework defined by the following set of equations
z “Xβ ` εz, (1.1)
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ẑ “ X̂β, (1.2)
y “ aẑ ` εy, (1.3)
where equation 1.1 represents the training model for the gene expression reference panel
with z being a vector of size n1 denoting the gene expression measurements, andX being
an n1 ˆ p genotype matrix for p cis-SNPs of the gene. Equation 1.2 represents the gene ex-
pression prediction model for the analytical sample with ẑ being a vector of size n2 denoting
the predicted gene expression measurements, and X̂ being an n2 ˆ p genotype matrix for p
cis-SNPs of the gene, matching those from equation 1.1. Equation 1.3 represents the pheno-
type association model for the analytical sample with y being a vector of size n2 denoting
the quantitative trait (or binary trait in extensions of the method), ẑ is the vector of predicted
gene expression measurements from equation 1.2, and a is the effect size on which we wish
to make inferences. In equations 1.1 and 1.2, β is a vector of length p of the effect sizes of
the cis-SNPs on gene expression. In each of the above models, εz and εy are error terms and
follow multivariate normal distributions Nn1p0, σ
2
zIn1q and Nn2p0, σ
2
yIn2q, respectively.
In the following sections we discuss how the above modeling framework differs for var-
ious frequentist and Bayesian approaches to TWAS in terms of the assumptions that they
impose on the estimation of β, the SNP-gene effect sizes. Table 1.1 provides a summary
(adapted from Zhu and Zhou (2020)) of the TWAS methods discussed below.
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Table 1.1: A summary of the TWAS methods described in section 1.2 and adapted from Zhu and Zhou (2020).
Methods Year Design Tissue Data type Assumptions URLs
PrediXcan 2015 Two-stage Single Individual Elastic net
https://github.com/hakyimlab/
PrediXcan
S-PrediXcan 2018 Two-stage Single Summary Elastic net
https://github.com/hakyimlab/
MetaXcan






DPR 2017 Two-stage Single Individual DPR http://www.xzlab.org/software.html















































fQTL 2017 Two-stage Multiple Summary BVSR https://github.com/ypark/fqtl





JTI 2020 Two-stage Multiple Summary https://github.com/gamazonlab/MR-JTI






In the first landmark approach to TWAS analysis, Gamazon et al. (2015) introduce the
PrediXcan method which employs elastic net as the modeling assumption on β. Specifically,
elastic net assumes that each element of β follows a linear combination of LASSO (Tibshi-
rani, 1996) and ridge regression (Hoerl and Kennard, 2000) (with penalties L1 and L2, respec-
tively) on the cis-SNP effect sizes. Thus, the model imposes the following penalty terms on β
λ1||β||1 ` λ2||β||2, (1.4)
where ||.||1 and ||.||2 denote the L1 and L2 norms, respectively. Assuming the model in
equation 1.4, PrediXcan obtains the β estimates in equation 1.1, uses them to predict the
genetically-regulated component of gene expression in equation 1.2, and performs the as-
sociation analysis in equation 1.3 to obtain the estimate of gene expression effects on the
phenotype. Thus, PrediXcan relies on the combined penalties imposed by elastic net as a
variable selection method to select a sparse set of cis-SNPs with non-zero effects on gene
expression. In one example of PrediXcan’s use, among many, it has helped to identify novel
genes associated with breast cancer risk which exhibit potential biological mechanisms for
impacting breast carcinogenesis (Hoffman et al., 2017). In particular, Hoffman et al. (2017)
find decreased expression of DHODH in breast tissue associated with breast cancer risk, and
although the authors note that the direction of the association between DHODH and breast
cancer has been inconsistent in the literature, DHODH inhibition has been leveraged in the
treatment of breast cancer.
In another frequentist approach to TWAS, Yang et al. (2019) propose a collaborative
mixed model (CoMM) to investigate the mechanistic role of associated variants on complex
traits. CoMM essentially adopts the same modeling framework as described in equations 1.1-
1.3. However, while other methods such as PrediXcan, MetaXcan (Barbeira et al., 2018b) and
TWAS/FUSION (Gusev et al., 2016) employ a two-step estimation procedure ignoring the
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uncertainly of equation 1.1, CoMM jointly estimates the models in equations 1.1-1.3 in order
to capture the uncertainty inherent in model 1.1. Thus, the modeling assumption imposed on
the effect sizes, β, in CoMM is the normality assumption given by
βj „ Np0, σ
2
βq, (1.5)
and the normal distribution of y includes an additional variance term representing the uncer-
tainty from model 1.1. Here, when uncertainty does indeed exist in model 1.1, as is likely the
case, the estimation of the variance parameter σ2y would be biased upward. Thus, account-
ing for uncertainty in model 1.1 by jointly estimating the three equations together, CoMM is
statistically more efficient than methods that ignore this uncertainty. CoMM then uses a likeli-
hood ratio test to evaluate the significance of the gene-trait association. While this likelihood-
based framework tends to be less flexible than Bayesian approaches, it often exhibits a sub-
stantial power gain over other approaches including PrediXcan and TWAS/FUSION. The
probabilistic Mendelian randomization method (PMR, Yuan et al. (2020)) employs this same
likelihood-based TWAS framework. In a combined collection of five GWAS data sets in-
cluding 64 phenotypes, Yang et al. (2019) and Yuan et al. (2020) show CoMM’s and PMR’s
increased power over, e.g. PrediXcan, to detect TWAS-significant signals across the genome
and identify novel gene-trait associations with asthma, C-reactive protein, type I diabetes, and
other complex diseases.
1.2.1.2 Bayesian Approaches
TWAS/FUSION (Gusev et al., 2016) is one method which uses a Bayesian sparse linear
mixed model (BSLMM, Zhou et al. (2013)) to estimate β. This modeling approach can be
thought of as a hybrid between a linear mixed model and a sparse regression model (e.g.
Bayesian variable selection regression; BVSR; Guan and Stephens (2011)) and assumes
that the effect size of each cis-SNP on gene expression follows a mixture of two normal
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distributions given by




b q ` p1´ πqNp0, σ
2
b q. (1.6)
This model can be interpreted as assuming that all variants have at least a small effect, which
are normally distributed with variance σ2b , and some proportion of variants π have an addi-
tional effect which is normally distributed with variance σ2a. Thus, the BSLMM assumption
categorizes SNPs into two groups, namely a small group of SNPs (π) with large effect sizes
and a larger variance, and a large group of SNPs (1 ´ π) with small effect sizes and smaller
variance. With this modeling assumption, TWAS/FUSION seeks to estimate the β effects
in equation 1.1, then plugs the β estimates into equation 1.2 to predict gene expression, and
finally performs the association step (equation 1.3) to estimate the gene-trait effects. The flex-
ible framework of the BSLMM allows it to perform well across a wide range of phenotypes
(including prostate cancer [Mancuso et al. (2018)] and schizophrenia [Gusev et al. (2018)])
and tends to perform better than models which only include the single best cis-eQTL or mod-
els which use all SNPs in the locus.
Another type of modeling assumption on β, which is implemented in the Dirichlet pro-
cess regression (DPR, Zeng and Zhou (2017)) and the TIGAR (Nagpal et al. (2019)) meth-
ods, is called the latent Dirichlet process regression. Dirichlet process regression is a non-
parametric method which relies on the Dirichlet process to flexibly and adaptively model
the effect size distribution itself, rather than using a fixed parametric distribution as the prior
choice for the effect size distribution. In this way, DPR uses infinitely many parameters a pri-
ori to characterize the effect size distribution, achieving robust predictive performance. Thus,
DPR assumes that each element of β follows a normal distribution, with a further unknown
distribution G placed upon the variance parameter, and infers the unknown distribution G by
placing a non-parametric Dirichlet process (DP) prior on the distribution itself, given by




j „ G,G „ DPpIGpa, bq, λq, (1.7)
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where the inverse gamma (IG) distribution is the base distribution and the concentration
parameter λ determines how the distribution of G differs from the base distribution. In a
similar fashion as the other methods, with the DPR modeling assumption on β, one obtains
the estimates of β in equation 1.1, then plugs the β estimates into equation 1.2 to predict
gene expression, and finally performs the association step (equation 1.3) to estimate the gene-
trait effects.
In simulations and real data analysis, DPR typically achieves better predictive perfor-
mance compared to elastic net (as in PrediXcan) or other Bayesian methods, which generally
translates to higher power to detect significant genes in the association step. However, the
biggest limitation with DPR is with its computational time, as it uses a Markov Chain Monte
Carlo-based approach and a Gibbs algorithm that is computationally slow. Additionally, at the
present time, DPR is only suitable for continuous phenotypes and has yet to be extended to
the analysis of binary phenotypes.
Finally, the Factored QTL method (fQTL, Park et al. (2017)) uses the BVSR modeling
assumption in the context of TWAS. BVSR places a sparse modeling assumption on the
genetic effects of gene expression and assumes that each element of β follows a point-normal
distribution given by
βj „ πNp0, σ
2
βq ` p1´ πqδ0, (1.8)
where a small proportion (π) of βj are non-zero and follow a normal distribution, and a larger
proportion (1´π) of βj are zero, with δ0 indicating a point mass at zero. fQTL is a multi-tissue,
multivariate model for mapping eQTLs and predicting gene expression, and thus more details
are given in section 1.2.2.
1.2.1.3 Methods Conclusion
Each TWAS method highlighted above places a different modeling assumption on the
estimation of β and is considered from a frequentist or Bayesian framework. Most existing
TWAS methods employ a polygenic modeling assumption and perform well across a wide
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range of applications. This fits well with the polygenic architecture likely underlying gene
expression levels. Additionally, polygenic models such as LMM, BSLMM, and DPR often
outperform sparse models such as elastic net and LASSO (e.g. PrediXcan) in predicting gene
expression and tend to be more flexible. However, model flexibility tends to precede compu-
tational difficulty, and thus, most methods (with the exception of likelihood methods such as
CoMM) rely on a two-step procedure to predict the genetically-regulated component of gene
expression and then associate these predicted transcripts with the phenotype of interest. This
trade-off between model flexibility, power gain, and computational efficiency are key aspects
to consider when performing a TWAS.
1.2.2 Single versus Multiple Tissue Association
One important detail to consider when performing a TWAS is the gene expression ref-
erence panel with which model 1.1 will be estimated. Although gene expression reference
databases are becoming more abundant, the sample sizes of these databases remain small,
relative to GWAS data sets. Performing TWAS using a small, albeit relevant, gene expression
tissue reference panel can suffer from poor model training quality, which may in turn nega-
tively impact the prediction accuracy of model 1.2 and lower the confidence of the inferences
made based on model 1.3. Nonetheless, in the early stages of methodological development,
the focus was on univariate analysis (i.e. analyzing one trait and one gene at a time) (e.g.
PrediXcan 2015, TWAS/FUSION 2016, DPR 2017, TIGAR 2019, CoMM 2019, PMR 2020).
In some cases, a single-tissue approach has advantages over a multi-tissue approach to TWAS,
particularly when tissue-specific effects are important in investigating the genetic nature of,
for example, a life-threatening heart disease such as calcific aortic valve stenosis (Thériault
et al., 2018). While these single-tissue analyses have certainly enabled greater power to de-
tect gene-trait associations missed by GWAS (as highlighted throughout this chapter), the
sharing of eQTLs across tissues and substantial correlation between different tissues points
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to the benefits that may be gained by aggregating eQTL evidence more efficiently and jointly
testing the effects of gene expression variation from different tissues.
Thus, multivariate TWAS methods such as the tissue-specific collaborative mixed model
(TisCoMM 2019b), an extension of CoMM (section 1.2.1.1), have been proposed to leverage
the co-regulation of cis-genetic variations across multiple tissues. Specifically, TisCoMM
regresses expression data across multiple tissues on genotype by the following multiple re-
gression model
Zn1ˆm “Xn1ˆpBpˆm ` εz,n1ˆm (1.9)
where mpk “ 1, ...,mq denotes the number of tissues, Z is the expression matrix with each
column representing a tissue measured from n1 samples,B is the genetic effect matrix with
dimension pˆm, and εz is the n1ˆm error term. Then the association model extends naturally
from equations 1.2 and 1.3 as follows
y “ X̂n2ˆpBpˆmamˆ1 ` εy,n2ˆ1 (1.10)
where amˆ1 “ pa1, ...ak, ...amq is a vector of causal effects with each element indicating the
effect of gene expression in each tissue on the phenotype. As with CoMM, TisCoMM uses
the likelihood ratio test to make inference on amˆ1. Similar to TisCoMM, UTMOST (Hu
et al., 2019) uses the expression model given in equation 1.9, and estimatesB by minimizing
the squared loss function with a LASSO penalty on the columns (within-tissue) and a ridge












whereB.k represents the genetic effect sizes of p SNPs in the k-th tissue, andBj. represents
the genetic effect sizes of the j-th SNP across all m tissues. UTMOST has been used to iden-
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tify novel gene associations with various brain structures in imaging genetics (Zhao et al.,
2019).
MultiXcan (Barbeira et al., 2018a) leverages the substantial sharing of eQTLs across
multiple tissues by regressing the phenotype of interest on the predicted expression from





akẑk ` εy, (1.12)
where ẑk is a vector of the predicted expressions in tissue k, and ak is the causal effect of
gene expression in the k-th tissue on phenotype y. MultiXcan then uses an F-test to assess the
joint significance of the regression across the multiple tissues.










where bsnp denotes the SNP-dependent genetic effect component and btis denotes the tissue-
dependent genetic effect component, representing a decomposition of the SNP effect of the
j-th SNP in the k-th tissue. As mentioned in section 1.2.1.2, fQTL assumes the BVSR prior
and estimates the posterior distribution of bsnp and btis by optimizing the variational objective
function via stochastic variational inference.
Joint-tissue imputation (JTI, Zhou et al. (2020)) is a more recently developed framework
for incorporating multiple tissues which uses an alternative imputation approach by borrow-
ing information across tissue transcriptomes. The approach leverages shared genetic regula-
tion from the other tissues in a tissue-dependent manner. Furthermore, JTI uses Mendelian
randomization as a causal inference strategy for TWAS.
1.2.3 Individual Level versus Summary Data
For many large-scale analyses, individual level GWAS data are not available and re-
searchers must rely solely on summary statistics, and summary statistics themselves are be-
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coming much more readily available from large-scale association studies, which may include
hundreds of thousands of individuals. Thus, the use of these substantial GWAS summary
statistics databases can give TWAS a considerable boost in statistical power. Additionally,
summary-based analyses benefit from lower computational cost and computing memory stor-
age as compared to individual level analyses (Zhu and Zhou, 2020). Thus, software packages
that allow for the use of these summary statistics provide much more flexibility for perform-
ing a broad range of TWAS analyses. Methods such as PrediXcan (S-PrediXcan) and CoMM
(CoMM-S2) (section 1.2.1) have extended their methodology to use summary-based statis-
tics to perform TWAS, while others, such as UTMOST, fQTL, and FOCUS use summary
statistics directly. Still others (PMR, TIGAR, TWAS/STWAS, MultiXcan/S-MultiXcan and
Tis-CoMM/Tis-CoMM-S2, MOSTWAS) are adapted for the use of either individual-level or
summary statistics. Summary-based methods such as S-PrediXcan and MetaXcan, for ex-
ample, have been used to identify novel associations with blood pressure determinants (Giri
et al., 2019) and age at natural menopause (Shi et al., 2019a), respectively.
In general, each of the summary-based methods requires as input GWAS association
statistics in terms of marginal z-scores, as well as a SNP LD matrix, either obtained from a
sub-sample of the original GWAS or from a reference panel. However, LD reference pan-
els should be carefully considered, particularly in terms of how well the ancestry of the LD
matrix matches that of the GWAS population. Ancestry-specific LD reference panels are
still not widely available and this may limit the use of summary-based TWAS methods when
analyzing minority ancestry or admixed populations. Additionally, summary-based TWAS
methods limit the ability to perform post-processing of results via conditional analysis. How-
ever, GCTA-COJO (Yang et al., 2012) can be used to approximate conditional analysis, by
conditioning the GWAS summary statistic on a variant or set of variants, and then re-running
TWAS using the conditional GWAS result. Although, GCTA-COJO also relies on an LD ref-
erence panel, and thus does not perform well in admixed populations or for rare transcripts or
conditional variants.
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1.2.4 Integration of Distal Variants
Traditional TWAS methods focus on local genetic regulation of transcription, typically
within a 1 megabase (Mb) region of the gene, and ignore any distant variants that may indeed
significantly contribute to gene expression. Recent work in transcriptional regulation has
estimated that distal genetic traits account for up to 70% of the variance in gene expression
(Brynedal et al., 2017; Liu et al., 2019), suggest that regulatory networks are so intercon-
nected that a majority of genetic variants in the genome, local or distal, have indirect effects
on the expression level of any particular gene (Liu et al., 2019; Boyle et al., 2017), and even
biologically simple traits, such as testosterone, can show enrichment of significant genetic
signal near genes involved in relevant pathways, though this mapping is often clearer for
intermediate phenotypes and biomarkers (Sinnott-Armstrong et al., 2020). This evidence sug-
gests that phenotypic variance may be driven by variants distal to the gene and spread across
the genome, and that incorporating distal variants into the analysis could improve transcript
prediction.
Thus, more recently, methods such as MOSTWAS (Multi-Omic Strategies for Transcriptome-
Wide Association Studies, Bhattacharya et al. (2020)) have been proposed as a multi-omic
strategy that extends TWAS by incorporating 1) SNPs local to mediating biomarkers that
are highly associated with gene expression, and 2) highly mediated distal-eSNPs (i.e. distal
variants associated with gene expression). Through simulation and real data examples, the
authors demonstrate MOSTWAS’s improvements in percent of variance explained and power
to detect gene-trait associations over typical TWAS. MOSTWAS also aids in identifying pos-
sible mechanisms for gene regulation by using a novel added-last test to assesses whether
significant information is gained from the distal variants beyond the local association. While
the computational burden of MOSTWAS may be a concern, the authors have designed the
software with parallel implementation using multiple cores and batch computing, and suggest
that by making standard distributional assumptions of the SNP-mediator and mediator-gene
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effect sizes, MOSTWAS’s gain in predictive performance and power to detect gene-trait asso-
ciations outweighs the computational cost.
Bayesian Genome-wide TWAS (BGW-TWAS, Luningham et al. (2020)) is another re-
cently developed method which leverages both cis- and trans-eQTLs of the target gene and
is based on BVSR, enabling efficient computation by using summary statistics from standard
eQTL analyses. This remains an intriguing area for TWAS methodological development and
improvements in computational efficiency, particularly as larger multi-omic panels which
provide large sets of mediating biomarkers become more widely available. Together these
methods further enrich our understanding of the complex interactions underlying genetic
regulation within tissue and identify important risk genes.
1.3 TWAS Challenges and Solutions
TWAS provide many advantages over GWAS, including reducing the multiple testing bur-
den, potentially detecting true signals missed by GWAS, and helping to identify the biological
mechanisms underlying the associations identified by GWAS. However, as TWAS continue
to identify thousands of statistically significant and/or novel signals across the genome, it
becomes more important to distinguish between causal and spurious signals. The sections that
follow highlight many of the challenges that arise with TWAS, many of which were summa-
rized by Wainberg et al. (2019). Along with each challenge, we present possible solutions
and other considerations.
1.3.1 TWAS Signals Driven by Known GWAS Variants
One of the advantages of TWAS is in its power to potentially detect signals across the
genome that were previously missed by GWAS. However, previously identified GWAS sig-
nals can often drive observed TWAS signals, and especially in very well studied phenotypes,
discovering a true novel signal can be challenging. In this case, we recommend performing
conditional analysis by adjusting for individual variants previously known to affect the pheno-
15
type, to evaluate if TWAS-identified genes represent novel statistical signals or were primarily
driven by single variants known from GWAS. Briefly, we recommend conditioning the pre-
dicted gene expression value of each statistically significant TWAS gene on the set of cis (e.g.
within ˘ 1 Mb of the gene) sentinel GWAS variants for the phenotype.
Several software packages, such as cpgen (https://github.com/cheuerde/cpgen) (with
slight modifications for larger sample sizes), BOLT-LMM (Loh et al., 2015, 2018), and RE-
GENIE (Mbatchou et al., 2020), can be used to perform a flexible variety of conditional
analyses (e.g. conditioning GWAS on TWAS, conditioning TWAS on GWAS, etc.) while
accounting for a relationship matrix. cpgen and BOLT-LMM tend to perform well if only a
small number of conditional analyses are needed (e.g. for a single phenotype), and REGENIE
has computational gains when performing conditional analyses on groups of variants, genes,
or phenotypes in very large sample sizes. TWAS/FUSION can be used to condition each
GWAS variant on the index TWAS gene or on the set of candidate causal genes at a given lo-
cus, and GCTA-COJO can use summary statistics for conditional analysis as noted in section
1.2.3.
1.3.2 TWAS Loci Containing Multiple Signals
TWAS can prioritize candidate causal genes at GWAS loci. However, TWAS-significant
loci may contain multiple trait-associated genes which can obscure the identification of a
causal gene. This may be due to co-regulation either because of correlated total or predicted
gene expression among genes at a locus and/or because of the sharing of predictive model
variants among genes. Thus, the interpretation of TWAS findings at these locations may be
particularly challenging.
Co-regulation among genes at a multi-gene TWAS locus is typically measured by total or
predicted expression correlation. Wainberg et al. (2019) note that genes strongly correlated
in their total expression with a strong TWAS signal tend to also be TWAS signals. Thus,
correlation of total expression across individuals can cause spurious results. Wainberg et al.
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Figure 1.1: Wainberg et al. (2019) SORT1 locus. Co-regulation strongly predicts TWAS hit
strength at the SORT1 locus. a, Fusion Manhattan plot of the SORT1 locus. b, Expression
correlation (corr.) with SORT1 versus TWAS P value, for each gene in the SORT1 locus. Chr,
chromosome.
(2019) demonstrate that a multi-gene locus may indeed only contain one most likely causal
gene, for example the SORT1 locus in LDL/liver, even though a set of genes likely to be non-
causally related to the phenotype may also be identified as TWAS significant at the same
locus (i.e. SARS, CELSR2, PSRC1, PSMA5, ATXN7L2, SYPL2, AMIGO1, and GSTM4 are
also prioritzed by TWAS at the SORT1 locus.) (Figure 1.1). The likely non-causal genes
at a locus may only be prioritized by TWAS due to their correlation with the causal gene.
For example, at the SORT1 locus, the TWAS p-values of the eight other likely non-causal
genes are highly related to their expression correlation with SORT1 (Spearman correlation =
0.75). Correlated predicted expression may also cause false hits, even in the absence of total
expression correlation. In a gene pair, this could be due to the same causal eQTL regulating
both genes or two causal eQTLs in LD each regulating one of the genes (Mancuso et al.,
2019), and these different scenarios are not designed to be distinguishable by TWAS.
Additionally, the sharing of variants (or LD partners of these variants) among predic-
tive gene models at a locus could also result in false TWAS signals, even in the absence of
correlated predicted expression (Wainberg et al., 2019). In this case, predicted expression
correlation may be low because other variants that are distinct between the models may have
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Figure 1.2: Wainberg et al. (2019) NOD2 locus. Sharing of GWAS variants between
expression models can contribute to non-causal hits even without correlated predicted
expression. a, Fusion Manhattan plot of the NOD2 locus. b, Details of the expression models
of NOD2 and BRD7; a line between a variant’s rs number and a gene indicates that the variant
is included in the gene’s expression model with either a positive weight (blue) or a negative
weight (orange), with the thickness of the line increasing with the magnitude of the weight.
Red arcs indicate LD.
a diluting effect on the correlation. Wainberg et al. (2019) show that this could be true if the
strongest signal gene, say GENE1, at a locus places the most weight on a variant which hap-
pens to be the strongest GWAS signal in another gene’s (GENE2) model, and the model for
GENE2, instead, places the most weight on a weaker (or selection of weaker) GWAS hit(s)
(e.g. NOD2 locus, Figure 1.2). This type of co-regulation is not captured by gene expression
correlation.
TWAS loci containing multiple signals pose a particularly challenging scenario for iden-
tification of the causal gene and, generally, interpretation of TWAS findings. Identifying the
most likely and biologically plausible gene at a multi-gene locus is an area with many oppor-
tunities for methodological development. One emerging area to address co-regulation (either
due to correlated expression or shared GWAS variants) is in TWAS fine-mapping, using soft-
ware such as FINEMAP or FOCUS (discussed in more detail in section 1.3.4). However,
these software have their own limitations. If individual level data are available, joint analyses
could be conducted to jointly infer the effects of predicted gene expression on a phenotype
using penalized regression (Wainberg et al., 2019). At the very least, researchers should care-
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fully examine the relative association strengths among the genes at a locus when interpreting
TWAS results.
1.3.3 Considering a Relevant Reference Panel
Selecting a relevant gene expression tissue reference panel is an important decision to
consider because predicting expression using non-trait-related expression panels may pro-
duce spurious TWAS signals (Wainberg et al., 2019). A trait’s most mechanistically related
tissue should be used to predict gene expression when possible, and consideration should be
taken to balance the trade-off between tissue bias and reference panel sample size, otherwise.
Researchers should be cautious not to over-interpret TWAS findings that may be prone to
substantial tissue bias because this bias can unexpectedly alter the pattern of TWAS p-values
and effect sizes (Wainberg et al., 2019).
Emerging topics in this area to address this issue include the use of multi-tissue TWAS
methods such as UTMOST and MulTiXcan (described in section 1.2.2), which leverage the
substantial sharing of eQTLs across multiple tissues by regressing the phenotype of interest
on the predicted expression from multiple tissues at a time. Employing these methods helps
to alleviate tissue bias and increase sample size. Additionally, ancestry-specific expression
predictions should be conducted when possible, rather than simply relying on a European
reference panel, for example (Mogil et al., 2018). Finally, the generation of very large expres-
sion panels, in European and minority populations, to utilize trans eQTL signals will provide
substantial improvements in expression prediction across a wide range of phenotypes.
1.3.4 Fine-mapping
Taking a step back, the goal of fine-mapping a GWAS is to determine which variants in
a genomic region are most likely to be causally related to a trait, after accounting for how
the variants in the region are correlated. In TWAS, the focus is on identifying which genes
in a genomic region are likely to be causally related to the trait. Not only is it important to
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account for how the genes in the region are correlated, but it is also important to account for
the correlation among predictive model variants at the region.
The FINEMAP software (Benner et al., 2016) provides a starting framework for achiev-
ing this task. FINEMAP is a software package to efficiently explore a set of the most im-
portant causal configurations of the region via a shotgun stochastic search algorithm and
produces accurate results in a reasonable processing time. Although FINEMAP was origi-
nally developed for GWAS fine-mapping, it can be “tricked” into TWAS fine-mapping by
substituting genotype information for predicted gene expression. It takes into account the
correlation among the predicted expression of genes at a genomic region and outputs a credi-
ble set of causal genes at this region. This method is easily adapted to the TWAS framework
and relatively efficient on large sample sizes such as UK Biobank. However, FINEMAP does
not account for the LD pattern of variants at the locus, nor does it account for the inevitable
sharing of variants among predicted gene expression models.
Mancuso et al. (2019) developed the FOCUS method (fine-mapping of causal gene sets)
which utilizes the LD pattern of variants within a genomic region in order to infer the pre-
dicted correlation among genes at the locus. FOCUS also attempts to extend TWAS from
modeling one gene at a time towards modeling multiple genes simultaneously. The software
takes as input GWAS summary data, expression prediction weights, and LD among all SNPs,
and estimates the probability of any given set of genes containing the causal gene(s).
While FOCUS is computationally efficient, it has many challenges when applied to some
typical TWAS analysis settings. First, FOCUS performs TWAS and fine-mapping somewhat
simultaneously by using a summary statistics-based TWAS method to predict gene expres-
sion, requiring summary GWAS data, an LD reference panel, and a database of the weights
used for predicting gene expression. This may perhaps seem convenient, but it limits the re-
searcher’s ability to use the TWAS method of their choosing. For example, researchers often
train their own predictive models on a set of cohort-matched variants, predict gene expression
using individual-level genotype data, and then associate those predicted transcripts with their
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phenotype of interest. In this case, it would be beneficial to re-implement the FOCUS soft-
ware such that it can perform fine-mapping on a set of pre-calculated TWAS summary statis-
tics based on the researcher’s TWAS method of choice. Without this capability, researchers
are restricted to using a summary statistics-based TWAS method that may not provide an
exact variant match to the researcher’s analytical cohort.
Second, the FOCUS software requires very restrictive data formats that are not well doc-
umented. Although the software allows researchers to theoretically import weights from
PrediXcan, for example, in practice it requires a weights database to be formatted like the
GTEx weights databases from PrediXcan in PredictDB. Thus, even the DGN weights database
that is available from PredictDB has to be artificially manipulated in order to import to FO-
CUS. Again, this type of poorly-documented, restrictive format not only hinders the soft-
ware’s ease of use but also limits a researcher’s ability to import their own model-trained
weights for fine-mapping. In general, the FOCUS software is a relatively recent development
with several opportunities for improvement that would facilitate broader applicability to a
variety of TWAS settings.
Fine-mapping of gene sets (FOGS; Wu and Pan (2020)) is another software that can
perform statistical fine-mapping over gene sets in a locus by testing whether the conditional
effects of SNPs in each gene is null. The conditional effect is estimated from a joint regres-
sion model including all the SNPs in a locus. The authors first estimate the conditional effects
for the SNPs via ridge regression. They then apply an adaptive test, called aSPU (Pan et al.,
2014), to combine the conditional effects and eQTL-derived weights effectively. Through
simulations, Wu and Pan (2020) show that FOGS outperforms FOCUS and adequately con-
trols type I error rates. However, the simulations themselves, examples that the authors chose
to highlight their results, comparisons with FOCUS, and methodological framework are not
immediately convincing. At this stage, FOGS has not been widely cited and its utility is yet to
be determined.
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Although fine-mapping can help to identify a credible set of causal genes within a locus,
it does not, by definition, automatically pinpoint the most biologically plausible gene, so care
still needs to be taken when interpreting TWAS fine-mapping results. The prioritization of
causal genes at multi-gene loci remains an intriguing area of research with much opportunity
for methodological advancement.
1.4 Applying TWAS Framework to Other ’Omics Data
A natural progression from TWAS, which utilizes transcriptomic data, is to leverage
the TWAS framework to perform similar analyses in other types of ’omics data. In studies
seeking to analyze proteomics or metabolomics, for example, one may consider applying
the TWAS framework to predict these other ’omics measures in a cohort containing only
genotype data. Similar to TWAS, imputing metabolites, for example, using genetic variants is
less exact than direct measurement. However, genotype data are fairly inexpensive and widely
available, while obtaining metabolite data still poses a high cost. Furthermore, metabolite
imputation may have great clinical impact. Metabolome-wide association study (MWAS)
methods, without having to collect precious or even impossible tissue samples (e.g. tissues
unavailable in cohort studies, or tissues like muscle and adipose available in few cohorts)
and generate direct metabolite measurements, can be helpful for interpreting existing genetic
signals. Of the thousands of genetic signals identified for various phenotypes and complex
diseases, very few are functionally understood and linked to biological mechanisms, and
association of a genetically imputed metabolite, as opposed to a directly measured metabolite,
with phenotype is more suggestive of a causal versus correlational relationship.
Metabolites are closer to core biological processes than a complex disease phenotype
such as cancer or cardiovascular disease, and genetic variants significantly associated with
metabolite levels generally have larger effect sizes than is typical for GWAS analyses of com-
plex traits (Suhre et al., 2011; Yu et al., 2014). For example, 25 of the 37 loci identified in
an early European GWAS had effect sizes of 10-60% of metabolite levels per allele (Suhre
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et al., 2011). This suggests that metabolites may be useful as endophenotypes, and that her-
itable metabolites could be predicted from genotype data, similar to TWAS approaches for
gene expression. Thus, it is reasonable to consider adapting existing TWAS approaches to
create a novel MWAS approach which aggregates genetic variants by their associations with
a metabolite instead of an mRNA transcript. Similar extensions of the TWAS approach have
been successfully pursued for magnetic resonance imaging endophenotypes (Xu et al., 2017);
in this example, the authors predicted regional gray matter volumes from a reference dataset
and applied their predictive models to an Alzheimer’s disease GWAS, which subsequently
identified many Alzheimer’s disease related genes (Xu et al., 2017). It has been hypothesized
that MWAS may similarly identify strong links between metabolic processes and the genera-
tion and/or function of a variety of phenotypes. No studies to date are published in this arena,
and thus, there is much to be gained from a broader application of TWAS methods to other
’omics resources, including metabolites.
1.5 Conclusion
A variety of current TWAS methods which assess the effect of genetically-regulated
gene expression on phenotypes of interest have been proposed over the past five years. We
have seen how TWAS may provide us greater insight into the mechanisms underlying these
associations and discover novel associations previously missed by GWAS. However, there
remains much to be gained from TWAS analyses and a great deal to be learned regarding
the interpretation of TWAS findings and how these results fit into our broader understanding
of genetic variation, the biological and molecular basis for this variation, and the observed
measured phenotypes under study. TWAS could benefit from additional methodological
improvements simply in terms of flexibility for some methods and in the more challenging
computational efficiency for others. In the upcoming chapters, we perform TWAS on a large
European cohort using PrediXcan (Chapter 2) and introduce an R Shiny application and
R package (Chapter 3) to assist with interpretation of TWAS findings and investigate the
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challenges noted in section 1.3. In the final chapter (Chapter 4), we demonstrate and evaluate
how the TWAS framework may be applied to metabolomics data in a sample of European and
African Americans.
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CHAPTER 2: A LARGE SCALE TWAS OF TEN BLOOD CELL PHENOTYPES
REVEALS COMPLEXITIES OF TWAS FINE-MAPPING
2.1 Introduction
Hematological measures (red cell, white cell, and platelet traits) have a critical role
in oxygen transport, immunity, infection, thrombosis, and hemostasis and are associated
with many acute and chronic diseases, including autoimmunity, asthma, cardiovascular dis-
ease, and COVID-19 (Astle et al., 2016; Chen et al., 2020; Vuckovic et al., 2020; Foy et al.,
2020; Pence, 2020). Genome-wide association studies (GWAS) have identified thousands
of loci containing such trait-associated variants, and previous Mendelian randomization and
phenome-wide association study analyses have highlighted the likely causal role of blood
cell trait-associated genetic variants in a variety of disorders, including autoimmune condi-
tions and coronary heart disease (Astle et al., 2016; Chen et al., 2020; Vuckovic et al., 2020).
Unfortunately, these individual SNP-based GWAS make it difficult to identify regulatory
variants with small effect sizes which in aggregate impact the same gene, even in very large
sample sizes, and they identify regions of associated variants whose biological function is
often not clear (Gamazon et al., 2015). Thus, utilizing a gene-based method to aggregate the
effect of multiple regulatory variants may increase the study power to identify novel trait-
associated loci and elucidate mechanisms of biological function.
A transcriptome-wide association study (TWAS) is one gene-based method which sys-
tematically investigates the association between genetically predicted gene expression and
phenotypes of interest (Gamazon et al., 2015; Gusev et al., 2016; Zhou et al., 2020; Hu
et al., 2019). Here, we report results from a large TWAS of hematological measures using
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the PrediXcan method (Gamazon et al., 2015) to analyze data from 54,542 individuals of
European ancestry from the Genetic Epidemiology Research on Adult Health and Aging
(GERA) cohort (our discovery data set) (Kvale et al., 2015; Banda et al., 2015). Hematologi-
cal phenotypes are particularly good candidates for TWAS analysis due to the availability of
large RNA-sequencing datasets in a relevant tissue type, high heritability across traits, and
the large number of known genetic associations, most with poorly understood mechanisms
and target genes. We perform this analysis using whole blood RNA-sequencing in 922 indi-
viduals from the Depression Genes and Networks (DGN) (Battle et al., 2014) study as our
primary reference panel. After association analysis of imputed gene transcript levels with
hematological indices in GERA, we performed conditional analyses, adjusting for variants
previously identified to affect hematological measures, to evaluate if TWAS-identified genes
represented novel statistical signals or were primarily driven by variants known from GWAS
(Vuckovic et al., 2020). These direct conditional analyses represent a major advantage of
the use of individual level data for our TWAS analyses, since these conditional tests could
not be performed as easily or accurately using summary statistic-based methods. We repli-
cated our significant set of gene-trait associations in a meta-analyzed sample of TWAS results
containing 18,100 individuals from the Womens Health Initiative (WHI), 9,345 individuals
from the Atherosclerosis Risk in Communities Study (ARIC), and 8,455 individuals from
Mount Sinai BioMe Biobank (BioMe), all of European ancestry (Supplementary Table 1,
bioRxiv https://doi.org/10.1101/2021.02.23.432444). We also compared the TWAS results
from the primary DGN reference panel to three additional reference panels (whole blood and
Epstein-Barr virus (EBV) transformed lymphocytes from the Genotype-Tissue Expression
(GTEx) Project (The GTEx Consortium, 2017), and monocytes from the Multi-Ethnic Study
of Atherosclerosis (MESA, Mogil et al. (2018)); these are considered secondary reference
panels due to their smaller sample sizes. These additional analyses helped us to determine if
relevant tissues with smaller sample sizes support our primary TWAS findings with DGN.
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We employ several strategies to improve our understanding and interpretation of complex
genomic regions containing multiple TWAS-identified genes. First, we used FOCUS (fine-
mapping of causal gene sets; Mancuso et al. (2019)) to seek to identify a set of causal genes
within genomic loci containing multiple significant TWAS gene-trait associations. FOCUS
is a software used to fine-map TWAS statistics at genomic risk regions, while accounting
for linkage disequilibrium (LD) among variants and predicted expression correlation among
genes at those risk regions. Second, we present a novel web-based tool for integrating and
visualizing TWAS and GWAS results, as well as results from multiple expression reference
datasets. Additionally, we discuss frequently overlooked challenges of TWAS interpreta-
tion, such as failure to consider the number of proximal genes which cannot be accurately
imputed with a given reference panel, but which may still be influenced by variants identified
in GWAS studies. Our results illustrate the complexity of TWAS fine-mapping efforts but do
provide one resource for clarifying likely gene targets for blood cell trait-related genetic loci.
However, consideration of additional annotation resources and TWAS limitations is necessary
for confident identification of gene targets.
2.2 Results
We applied the PrediXcan method to identify expression-trait associations using in-
dividual level genotype and phenotype data from the GERA non-Hispanic white ethnic
group. Analyzed blood cell traits included platelet count (PLT), red blood cell counts (red
blood cell count (RBC), hematocrit (HCT), hemoglobin (HGB), mean corpuscular vol-
ume (MCV), and red cell distribution width (RDW) indices), and white blood cell counts
(white blood cell count (WBC), monocyte count (MONO), neutrophil count (NEUTRO),
and lymphocyte count (LYMPH) indices). We used DGN whole blood expression panel
weights from PredictDB (a database of weights provided by PrediXcan; see URLs) to pre-
dict gene expression levels in GERA. Among the 11,538 genes in the DGN expression
panel, 11,438 genes were predicted in GERA and 51% of those genes achieved DGN model
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R2 ą 0.05 (see Supplementary Table 2 for model R2 values for significant genes and
Supplementary Table 3 for genes included in DGN but not predicted in GERA, bioRxiv
https://doi.org/10.1101/2021.02.23.432444). The number of GERA variants used for pre-
diction was equal to the number of variants included in the prediction model (i.e. complete
variant matching) for 74% of the predicted genes; the remaining genes used fewer variants
from GERA than were included in the prediction models. We tested each of the 11,438 pre-
dicted genes individually for association with each of the 10 blood cell traits (BCTs), result-
ing in a Bonferroni-corrected p-value threshold of p ă 4.37ˆ 10´7. Through the subsequent
study analyses, we will refer to these results as “marginal TWAS”.
Overall, we identified 295 statistically significant marginal TWAS associations (p ă
4.37 ˆ 10´7), with each BCT having at least one significant association (Supplementary
Table 2, bioRxiv https://doi.org/10.1101/2021.02.23.432444). Among these, 47 marginal
TWAS associations fell into the major histocompatibility complex (MHC) or HLA region
(GRCh37; chr 6: 28,477,797 - 33,448,354) and were not considered in subsequent analyses
(Supplementary Table 4, bioRxiv https://doi.org/10.1101/2021.02.23.432444); disentan-
gling a set of causal genes within the MHC region is exceptionally difficult due to the highly
polymorphic genetic loci and complex LD in the region. Another 9 significant associations
included genes which contained only a single variant in the prediction model. These asso-
ciations were also not included in subsequent analyses (Supplementary Table 4, bioRxiv
https://doi.org/10.1101/2021.02.23.432444). The remaining 239 significant associations in-
clude genes predicted from 2 to 112 variants, with a median of 21 variants used in predictive
models. Among this set of 239 associations, we replicated 71 at p ă 0.05 with same direction
of effect for the blood cell trait in TWAS meta-analysis.
2.2.1 Conditional Analysis of Significant TWAS Genes
To determine whether any of the 239 remaining significant gene-trait associations were
novel signals, not driven by any previously reported genome-wide significant variant, we per-
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formed conditional analysis. Since we performed TWAS with individual level data, we con-
ditioned the predicted gene expression value of each statistically significant marginal TWAS
gene on the set of nearby (within ˘ 1 Mb of the gene) sentinel GWAS variants within the
BCT category (RBC, WBC, PLT) from the largest current European ancestry focused GWAS
for BCTs (Vuckovic et al., 2020). We found that 222 (93%) of all marginal TWAS signif-
icant associations were attenuated by known GWAS variants and became non-significant
(p ą 4.37 ˆ 10´7) upon conditional analysis. Another 15 of the associations remained
significant after conditional analysis, and the remaining 2 associations did not have GWAS re-
ported variants within a 1 Mb window of the gene (Supplementary Table 5, bioRxiv https:
//doi.org/10.1101/2021.02.23.432444). We attempted to replicate these 17
conditionally significant findings in a TWAS meta-analysis which included up to 32,036
European ancestry individuals from 3 cohorts: ARIC, WHI, and BioMe. Two of the 17 con-
ditionally significant gene-trait associations (HIST1H2BO-HGB and HIST1H2BO-RDW)
included in the replication set met the stringent significance threshold (p ă 2.94 ˆ 10´3).
However, HIST1H2BO is situated within 1 Mb of the MHC region already excluded above
(GRCh37; chr 6: 28,477,797 - 33,448,354), with this signal potentially reflecting long range
LD with the MHC region, and has poor model R2 “ 0.016. Additionally, OR2B6 associated
with HGB, MCV, and RWD; ZNF192 associated with HGB, MCV, and RDW; and ZSCAN12
associated with MCV meet a more lenient significance threshold (p ă 0.05). Yet, OR2B6,
ZNF192, and ZSCAN12 are also located on chromosome 6 within approximately 500kb of the
MHC region and all have poor model R2 ă 0.015. The remaining 7 gene-trait associations
did not meet any replication criteria.
2.2.2 Characterization of TWAS Identified Loci
Previously reported GWAS sentinel variants were at least partly responsible for and atten-
uated 93% of the significant marginal TWAS signals. Thus, we next examined if TWAS aided
fine-mapping and identification of regulatory mechanisms at these loci. To better contextual-
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ize if fine-mapping in GERA was consistent in additional cohorts, we also examined replica-
tion of TWAS significant genes in these known loci. The 239 marginal TWAS associations
reside in 120 trait-specific, physically non-overlapping cis loci (i.e. the cis region of each
locus is ˘ 1 Mb of the locus’s TWAS sentinel gene start and stop positions). Over half (57%)
of these loci contain only a single significant gene, while another 19% contain two significant
genes. The remaining 24% of non-overlapping loci contain three or more significant genes,
with up to 11 significant genes at a single locus. These 120 loci contain 87 unique index
genes (defined as the most significant TWAS gene within the locus). Most loci do not contain
a TWAS gene that replicates in meta-analysis (67% total; that is 47% of all loci are single-
gene loci that do not replicate plus 20% of all loci are multi-gene loci that do not contain any
gene that replicates, even at a marginal level). Ten percent of all loci are single-gene loci that
meet a marginal replication threshold (p ă 0.05), and 20% of all loci are multi-gene loci
that meet this marginal threshold for at least one gene at the locus. The remaining 4 loci (3%)
contain multiple TWAS genes with at least one gene meeting a strict replication threshold
(p ă 2.09ˆ10´4) (Supplementary Table 2, bioRxiv https://doi.org/10.1101/2021.02.23.432444).
These include the following index gene-phenotype associations: TRIM68-MCV, USP49-
MCV, PSMD3-NEUTRO, and PSMD3-WBC.
2.2.3 TWAS Fine-mapping
In order to facilitate TWAS fine-mapping and allow for better interpretation of whether
a given TWAS-identified gene is truly likely to associate with BCT variation, or whether it is
likely to be a spurious association due to correlation of expression with nearby genes or other
factors, we created an R Shiny application (called LocusXcanR) to interactively visualize
TWAS sentinel genes in context, one locus at a time. The application allows us to integrate
multiple sources of information from our primary TWAS analysis, including gene expression
prediction models, TWAS meta-analysis, TWAS using secondary reference panels (whole
blood and EBV transformed lymphocytes from GTEx, and monocytes from MESA), GWAS
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analysis of all BCTs, and correlation among genetic variants (i.e. LD) and among predicted
gene expression levels. We highlight several loci to demonstrate the utility of the applica-
tion, showcase some of the challenges that arise when TWAS identifies multiple significant
genes at a single locus, and illustrate some of the complexities that are inherent in TWAS fine-
mapping. In the sections that follow, we feature TWAS genes that fall into loci with a low,
intermediate, or high level of complexity. All the figures in the following sections originate
from the R Shiny application (http://shiny.bios.unc.edu/gera-twas/), which
could be readily adapted to future TWAS analyses for other complex traits.
2.2.3.1 HK1 Locus
The HK1 gene is known to be associated with several red blood cell traits including
hemoglobin, mean corpuscular volume, hematocrit, mean corpuscular hemoglobin, red blood
count, and red blood cell distribution width in GWAS analyses (Vuckovic et al., 2020) and
is a Mendelian gene for hemolytic anemia [MIM 142600]. Our TWAS results confirm pre-
viously reported HK1 GWAS associations with HCT and MCV (assigned based on nearest
gene for lead GWAS variants). The marginal TWAS tests for association between HK1 and
HCT (p “ 3.84 ˆ 10´8) and MCV (p “ 1.05 ˆ 10´7) are statistically significant (Fig 2.1);
associations are all but eliminated by conditional analysis on known GWAS sentinel variants
(HCT p “ 2.58 ˆ 10´1; MCV p “ 4.36 ˆ 10´2); HK1 with HCT replicates in meta-analysis
(p “ 4.63ˆ 10´2); and HK1 is the most significant TWAS gene among only two other genes
(HKDC1 and TSPAN15) implicated by GWAS at these loci, with the other two genes showing
no TWAS signal.
2.2.3.2 CREB5 Locus
The marginal TWAS tests for association between CREB5 and NEUTRO (p “ 1.41 ˆ
10´12) and WBC (p “ 4.01ˆ 10´10) are the only TWAS significant associations at this locus
(Fig 2.2A), and associations are essentially eliminated by conditional analysis on known
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Figure 2.1: HK1 locus (locus 60; chr 10: 70,029,740 - 72,161,638; trait = MCV) from R
Shiny. TWAS results (top panel) and GWAS results (bottom panel). Marginal and conditional
results for HK1 are presented in the top panel. Black colored genes and variants denote those
previously reported by UK Biobank and BCX GWAS (Vuckovic et al., 2020), blue variants
denote those not previously reported as UK Biobank and BCX GWAS sentinel variants.
GWAS sentinel variants (NEUTRO p “ 9.04ˆ 10´1; WBC p “ 3.97ˆ 10´1). However, at this
locus, both CREB5 and JAZF1 (TWAS NEUTRO p “ 5.26 ˆ 10´3, WBC p “ 2.42 ˆ 10´3)
have previously been annotated as being the nearest and/or assigned gene for one or more
GWAS sentinel variants. Predicted gene expression for CREB5 and JAZF1 are not highly
correlated (R2 between 0.0 - 0.2) and appear to share only a single, non-significant predictive
model variant (Fig 2.2B). CREB5 and JAZF1 both replicate at a lenient significance threshold
for NEUTRO (p “ 1.25ˆ 10´2, p “ 8.98ˆ 10´3, respectively), and CREB5 also replicates at
a lenient threshold for WBC (p “ 2.61ˆ 10´2) but JAZF1-WBC does not replicate (p “ 0.11).
Both genes appear in the GTEx whole blood (GWB) and MESA monocyte (MSA) secondary
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Figure 2.2: CREB5 locus (locus 40; chr 7: 27,338,940 - 29,865,511; trait = NEUTRO) from
R Shiny. TWAS results (top panels) and GWAS results (bottom panels). Marginal TWAS
result displayed in (A), with Black colored genes and variants denoting those previously
reported by GWAS, blue variants denote those not previously reported as GWAS sentinel
variants. (B) Mirrored-Manhattan locus-zoom plot displaying genes connected to their
predictive model variants. Color scale, increasing from light grey to red, indicates the
predicted expression correlation (R2) between the index TWAS gene and all other genes in
the locus and the LD between the index variant and all other variants in the locus.
reference panels, but neither gene meets the significance threshold for either reference panel.
Importantly, Human Protein Atlas (Uhlen et al., 2015) reports that CREB5 is enhanced in
blood and brain tissues and is specifically cell type enriched for NEUTRO (Human Protein
Atlas, 2020b). JAZF1 on the other hand has low tissue specificity (Human Protein Atlas,
2020d). Together the TWAS, GWAS, and Human Protein Atlas results point to CREB5 as the
most likely, and most biologically plausible, gene over JAZF1 at this locus.
2.2.3.3 CD164 Locus
The CD164 gene is known to play a role in hematopoiesis (Watt et al., 1998; Zannettino
et al., 1998) and has been associated with several blood cell indices in GWAS analyses (Vuck-
ovic et al., 2020). Our TWAS results prioritize CD164 over other genes at the locus as being
significantly associated with MCV (p “ 2.54 ˆ 10´12) and categorize it into a multi-gene
locus along with MICAL1 (p “ 4.20 ˆ 10´7) (Fig 2.3A). Conditional analysis on sentinel
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Figure 2.3: CD164 locus (locus 36; chr 6: 108,687,717 - 110,703,762; trait = MCV) from R
Shiny. (A) Marginal TWAS results in the top panel and GWAS results in the bottom panel.
Black colored genes and variants denote those previously implicated by GWAS, and blue
colored genes and variants denote those not previously implicated by GWAS. (B)
Mirrored-Manhattan locus-zoom plot displaying genes connected to their predictive model
variants. TWAS results in the top panel, GWAS results in the bottom panel. Color scale,
increasing from light grey to red, indicates the predicted expression correlation (R2) between
the index TWAS gene and all other genes in the locus and the LD between the index variant
and all other variants in the locus. (C) Comparison of marginal TWAS (left panel) and TWAS
meta-analysis (right panel). Black colored genes denote those previously implicated by
GWAS sentinel variants, and blue genes denote those not previously implicated by GWAS
sentinel variants.
GWAS variants all but eliminates the TWAS signal for both CD164 (p “ 8.61 ˆ 10´2) and
MICAL1 (p “ 1.26 ˆ 10´1). Interestingly, Fig 2.3B shows that CD164 and MICAL1 are
not highly correlated in their predicted gene expression (R2: 0.2 - 0.4), and do not share any
predictive model variants. We also note that both genes replicate in meta-analysis at a lenient
threshold (CD164 p “ 1.56ˆ 10´3; MICAL1 p “ 7.06ˆ 10´3; Fig 2.3C). Additionally, while
MICAL1 is not available in secondary reference panels, CD164 meets the TWAS significance
threshold for its association with MCV in GTEx whole blood and MESA monocytes (GTEx
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p “ 2.61ˆ 10´9 and MESA p “ 4.09ˆ 10´8). Thus, the evidence at this locus suggests that
expression of CD164 and MICAL1 are both reasonable candidates for being regulated by red
cell-associated genetic variants although we note that Human Protein Atlas reports low tissue
specificity for MICAL1 (Human Protein Atlas, 2020f).
2.2.3.4 PSMD3 Locus
The PSMD3 locus contains a much higher level of complexity because it falls into a
region containing many marginal TWAS genes, has a complex gene-gene correlation and LD
pattern, and includes a combination of genes previously reported by GWAS as well as genes
that have not been reported by GWAS. Thus, TWAS results do not clearly pinpoint the most
likely causal gene. While PSMD3 appears as the index TWAS gene associated with WBC
(Fig 2.4A), 8 other genes are also TWAS significant at this locus. Five of those genes (IKZF3,
GSDMB, ORMDL3, MED24, CCR7) replicate at a lenient significance threshold (p ă 0.05),
and PSMD3 replicates at a more stringent threshold (p ă 2.09 ˆ 10´4) (Fig 2.4C). We see a
complex network of shared model variants and correlation/LD patterns in Fig 2.4B, notably
with MED24 and CCR7 (the next most significant genes at this locus) being only slightly
correlated (R2 between 0.2 - 0.4) with PSMD3. The FOCUS fine-mapping results (Fig 2.4D)
correspond to the TWAS results and indicate PSMD3 and MED24 as the most likely causal
genes at the locus, each having posterior inclusion probabilities (PIPs) equal to 1.0. PIPs for
all other genes at this locus, including CCR7, are less than 0.021 (Fig 2.4D).
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Figure 2.4: PSMD3 locus (locus 101; chr 17: 37,137,050 - 39,154,213; trait = white blood
cell count). (A) displays marginal TWAS results (top panel) and GWAS results (bottom
panel), with genes and variants colored in blue and black to denote those not reported by
GWAS and those reported by GWAS, respectively. (B) is a mirrored-Manhattan locus-zoom
plot displaying genes connected to their predictive model variants with TWAS results (top
panel) and GWAS results (bottom panel). Color scale, increasing from light grey to red,
indicates the predicted expression correlation (R2) between the index TWAS gene and all
other genes in the locus and the LD between the index variant and all other variants in the
locus. (C) presents marginal TWAS results (left panel) and meta-analysis TWAS results (right
panel), with genes colored in blue and black to denote those not reported by GWAS and those
reported by GWAS, respectively. (D) displays the FOCUS posterior inclusion probabilities
(PIPs) for each gene at this locus.
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2.3 Discussion
We performed a large-scale TWAS using PrediXcan on 54,542 GERA individuals of Eu-
ropean ancestry and present compelling evidence that results from marginal TWAS analyses
alone cannot illuminate causal genes at loci for complex traits. We also present results of con-
ditional analysis of the TWAS significant genes. While 17 gene-trait associations did remain
significant after conditional analysis or contained no known GWAS sentinel variants within a
1 Mb region of the gene, we found no substantive evidence from meta-analysis nor secondary
reference panels to support these associations as novel discoveries for BCTs.
Conditional analyses suggest that nearly all our TWAS findings are driven at least in part
by GWAS sentinel variants from the largest recent European focused GWAS analysis for
BCTs (Vuckovic et al., 2020). Most gene-trait associations no longer meet our TWAS-wide
significance threshold after conditioning on GWAS sentinels. This is perhaps not surprising
given the greater statistical power for this GWAS analysis, which was conducted in 563,085
participants. However, for 61 gene-trait associations (26%), some residual signal (p ă 0.05)
remains after conditioning on GWAS. For example, although JAK2 is a well-known blood
cell-associated signal from GWAS (Vuckovic et al., 2020) and the Mendelian disease lit-
erature for platelet disorders (MIM 147796), its association with platelet count remained
statistically significant after conditional analysis. Thus, our TWAS results suggest that there
are likely additional regulatory variants at the JAK2 locus which are not tagged by current
GWAS single variants. Similarly, for other gene-trait associations retaining some residual sig-
nificance after conditional analysis our results suggest that additional small-effect regulatory
variants remain to be discovered for these genes which associate with blood cell indices. This
illustrates the power advantages from aggregate tests like TWAS.
We grouped the 239 TWAS-wide significant gene-trait associations into 120 loci for fine-
mapping. To effectively interpret these results, we introduce an R Shiny application which
integrates TWAS and GWAS information into locus-specific, interactive visualizations which
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we use to assist with TWAS fine-mapping and interpretation. We show the utility of the R
Shiny application in this endeavor by highlighting the varying levels of complexity at several
TWAS loci and demonstrating where TWAS aligns with or provides advantages over GWAS.
For example, the HK1-MCV locus shows a very simple genomic locus in which we find
that TWAS confirms what we already know from GWAS. HK1 is the predominant glucose
phosphorylating enzyme in mammalian tissues that share a strict dependence on glucose
utilization for their physiologic functions, such as brain, erythrocytes, platelets, lymphocytes,
and fibroblasts (Bianchi and Magnani, 1995), and coding variants in HK1 are known to be
associated with hemolytic anemia due to hexokinase deficiency [MIM 142600], providing
a clear link to red blood cell related traits. The CREB5 locus further demonstrates one of
the advantages of TWAS over GWAS in that the TWAS results provide clarity regarding the
likely causal gene at the locus. At this locus, CREB5 and JAZF1 have both been implicated
by GWAS, again, likely assigned based on their physical proximity to the GWAS sentinel
variant. However, CREB5 shows a strong TWAS signal, replicates in the much smaller meta-
analysis sample, and Human Protein Atlas provides clear evidence of enrichment in blood
(specifically neutrophils), as compared to JAZF1, which shows low blood and immune cell
specificity (Uhlen et al., 2015; Human Protein Atlas, 2020b,d). These results in aggregate
support CREB5 as the likely causal gene at this locus, even though CREB5 may not be the
closest gene in proximity to all sentinel GWAS variants within the region.
We specifically highlight the challenges, particularly at multi-gene loci, which should
be taken into consideration when interpreting TWAS findings, including total and/or pre-
dicted expression correlation, shared predictive model variants, relevance of reference tissue
panel, biological plausibility, etc. Furthermore, we demonstrate the importance of interpreting
TWAS results in context. Although TWAS is useful for prioritizing candidate causal genes, re-
searchers should guard against the hasty conclusion that the most significant gene is the only
causal gene or even the most likely causal gene. For example, the conclusion at the CD164 lo-
cus is not entirely clear based on TWAS results. While TWAS points to CD164 as the causal
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gene, as does existing knowledge of the genes biological function, taking the full context
of this locus into consideration, it is not out of the realm of possibilities that both CD164
and MICAL1 are causal at this locus. Furthermore, at the PSMD3 locus we see potentially
misleading TWAS results when marginal TWAS statistics are interpreted alone. The PSMD3-
WBC association appears as the sentinel gene at this locus. However, there are several pieces
of evidence which support other genes, including CCR7, as the most likely biologically plau-
sible causal gene at the locus. First, PSMD3 and MED24 are ubiquitously expressed across
tissues in Human Protein Atlas and have low tissue specificity and no immune cell speci-
ficity (Uhlen et al., 2015; Human Protein Atlas, 2020g,e). Additionally, results for these two
genes differ slightly by reference panel. MED24 appears in all secondary reference panels,
but only exceeds the significance threshold in GWB and MSA. On the other hand, PSMD3
only appears in the MSA reference panel and is not statistically significant in that panel. Sec-
ond, CCR7 is TWAS significant, it replicates at a lenient threshold in meta-analysis, and is
enriched for expression in blood and lymphoid tissues, especially T-cells (Human Protein
Atlas, 2020a). However, CCR7 is not highly correlated with nor does it appear to share model
variants with PSMD3, and the FOCUS results show a posterior inclusion probability of only
0.001. Finally, CCR7 is known to be involved in the migration of neutrophils to lymph nodes
(Beauvillain et al., 2011). While it is certainly possible at multi-gene TWAS loci for multiple
genes at the locus to be contributing to trait regulation, it is also possible for spurious or non-
relevant genes to be identified based on shared eQTLs across tissues which are not relevant to
a given trait or correlation of gene expression.
Moreover, proximal genes which cannot be accurately imputed with a given reference
panel, but which may still be influenced by variants identified by GWAS studies, must also
be considered. For example, the gene colony-stimulating factor 3 (CSF3), which has a known
key role in the production, differentiation, and function of granulocytes [MIM 138970],
is also situated within the PSMD3 locus. However, this gene has very low constitutive ex-
pression in whole blood (Human Protein Atlas, 2020c), and it is not depicted in Fig 2.4 be-
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cause a predictive model could not be fit for this gene in the DGN reference panel (likely
due to very low expression); therefore, CFS3 cannot be detected as a possible target gene
at this locus (Supplementary Table 7 contains CSF3, along with other genes that have been
assigned by one or more GWAS variants but are not included in DGN, bioRxiv https:
//doi.org/10.1101/2021.02.23.432444). This genomic region is extremely com-
plex and highly pleiotropic, and any interpretation of this locus using TWAS results alone
is likely to be overly simplistic. This complex locus shows the importance of considering
statistical evidence from TWAS, GWAS, and FOCUS fine-mapping as well as trait biology in
the interpretation of TWAS findings.
While we have used PrediXcan and pre-calculated PredictDB weights for our analysis,
we note a limitation in doing so. The variants included in PredictDB were not always avail-
able in our analytical cohort (generally due to poor imputation quality), so some predictive
models did not use all PredictDB weights. We note that 70% of our TWAS significant genes
were predicted with complete variant matching (i.e. used all model variants) and 85% of
TWAS significant genes used at least 90% of model variants; we have included this infor-
mation in Supplementary Table 2 (bioRxiv https://doi.org/10.1101/2021.02.23.432444) for
transparency, and these details should be taken into account when interpreting TWAS results.
The cohorts that we have included in our TWAS meta-analysis also pose some limitations
on our ability to replicate GERA TWAS sentinel genes. The smaller sample sizes of the
meta-analyzed cohorts are likely the primary reason why GERA TWAS sentinel genes fail to
replicate. Additionally, it may be the case that major contributing variants exhibit differential
allele frequencies across cohorts; although this is less likely than in multi-ethnic analyses
because all cohorts are of European ancestry, it could still contribute to poorer power for
replication. Furthermore, differences in imputation quality across cohorts could also explain
the failure to replicate TWAS sentinel genes in meta-analysis. Thus, future investigations
using homogeneously imputed data are needed to ensure consistency in imputation quality
across cohorts.
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Although FOCUS, in some cases, helps to identify a set of the most likely causal genes
at a locus, we have shown that it does not always provide enough evidence above and beyond
TWAS to fully identify a putative causal gene set at a complex locus. Additionally, FOCUS
performs a summary statistics-based TWAS method and then proceeds to fine-mapping the
TWAS results from this method. However, we performed TWAS using PrediXcan, and thus,
the fine-mapping results from FOCUS may not exactly match our PrediXcan TWAS results.
In future, the FOCUS software could be extended to take pre-calculated TWAS results as in-
put (using the TWAS method of the researchers choosing), bypassing the need to use GWAS
summary statistics or to re-compute predicted gene expression. Our analysis is primarily con-
ducted using whole blood TWAS weights only, with supplemental TWAS results available in
the LocusXcanR Shiny application for a few other blood-related tissues (whole blood and
EBV transformed lymphocytes from GTEx and monocytes from MESA) ; we felt this was the
most prudent approach to limit false positives and reduce needed multiple testing correction,
versus an approach using TWAS weights in, for example, all GTEx tissues, particularly given
the relatively large whole blood gene expression dataset available from DGN (N = 922). How-
ever, this choice could be inappropriate if the main relevant tissue at some blood cell-related
loci is not in fact whole blood, and it limits our ability to use FOCUS fine-mapping to over-
come choice of tissue for TWAS training. Joint/multiple tissue TWAS approaches such as
UTMOST (Hu et al., 2019) and MR-JTI (Zhou et al., 2020) could be employed in the future
to assess the relevance of other tissues at blood-cell related loci.
In summary, we found that TWAS results enrich our understanding of GWAS, can help to
explain trait variation, and are superior to merely selecting the nearest gene. We have shown
that the gene, or genes, implicated in TWAS, in some cases, clearly overlap with what is
known in GWAS and from prior knowledge of important genes in hematopoietic processes.
However, while we show that TWAS may help in some cases to pinpoint likely causal genes,
we emphasize the need for investigators to carefully interpret TWAS results together with
other ’omics data, in context. We introduce an R Shiny application and demonstrate its utility
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in assisting researchers in this endeavor by leveraging the TWAS and GWAS information
available from the analytical cohort and interactively visualizing results one locus at a time.
The results of this analysis are accessible online at http://shiny.bios.unc.edu/
gera-twas/, and we also make the layout of this application available for others to import
and analyze their own TWAS results in an R package called LocusXcanR, which is cur-
rently available on GitHub (https://github.com/amanda-tapia/LocusXcanR).
Together with a clearer understanding of the relationship between TWAS and GWAS results
and subject matter expertise, TWAS results can help us formulate mechanistic hypotheses for
functional experimental validation.
2.4 Materials and Methods
All cohorts are described individually below. We analyze 10 hematological phenotypes
(platelet count, red blood cell count, hematocrit, hemoglobin, mean corpuscular volume,
red cell distribution width, white blood cell count, monocyte count, neutrophil count, and
lymphocyte count) across all cohorts.
2.4.1 Ethics Statement
We here performed secondary data analysis on deidentified data only (exempt research).
All individual studies included were approved by relevant local institutional review boards,
and participants provided written informed consent.
2.4.2 PrediXcan Method
PrediXcan (Gamazon et al., 2015) is a gene-based association test that prioritizes genes
which are likely to be causal for the phenotype. It implements an elastic net-based method for
selecting variants associated with gene expression in a given reference panel, and then uses
those variants to predict gene expression in a cohort with only genotype data. We downloaded
the PrediXcan software (see URLs) along with its prepackaged weights for gene expression
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data from PredictDB (see URLs). Weights for gene expression using RNA sequencing data
were obtained from the Genotype-Tissue Expression project (version 7) (The GTEx Consor-
tium, 2017) (whole blood, genes = 6,208; and EBV transformed lymphocytes, genes = 3,000),
Depression Genes and Networks (Battle et al., 2014) (whole blood, genes = 11,538, n = 922),
and Multi-Ethnic Study of Atherosclerosis (Europeans only, monocytes, genes = 4,647) (Liu
et al., 2017). Imputed genotypes for all cohorts were filtered for imputation quality based on
R2 ą 0.3; variants not meeting this threshold were excluded from the analysis. We use DGN
as our primary reference panel for all TWAS analyses as it is the largest single whole blood
RNA-seq dataset.
2.4.3 Included Cohorts
These TWAS analyses were limited to self-reported white or European ancestry partici-
pants, for easy comparability with the DGN European ancestry eQTL panel, including input
of LD information into the R Shiny application (see R Shiny Methods), and with the largest
single-ancestry blood cell trait GWAS.
2.4.3.1 Genetic Epidemiology Research on Adult Health and Aging (GERA)
The GERA cohort includes over 100,000 adults who are members of the Kaiser Perma-
nente Medical Care Plan, Northern California Region (KPNC) and consented to research on
the genetic and environmental factors that affect health and disease, linking together clinical
data from electronic health records, survey data on demographic and behavioral factors, and
environmental data with genetic data (Kvale et al., 2015; Banda et al., 2015). By self-report,
the GERA cohort is 81% White and 19% minority. Each GERA participant provided a saliva
sample for extraction of DNA, which was conducted at KPNC using Oragene kits (DNA
Genotek Inc., Ottawa, ON, Canada). DNA samples were genotyped at the Genomics Core Fa-
cility of UCSF. Genotyping was completed as previously described (Kvale et al., 2015) using
4 different custom Affymetrix Axiom arrays with ethnic-specific content to increase genomic
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coverage. In addition to the QC protocols performed during genotyping, a total of six sub-
jects, all female, were dropped due to sex non-agreement according to the Plink v1.07 –geno
option and variants with more than 10% missingness were removed. Genotype data were
phased without external reference using Eagle v2.3 and then imputed to 1000 Genomes Phase
3 v5 using Minimac3. Principal components analysis was used to characterize genetic struc-
ture in this European sample Banda et al. (2015). Hematological measures were extracted
from medical records. In individuals with multiple measurements, the first visit with com-
plete white blood cell differential (if any) was used for each participant. Otherwise, the first
visit was used. In total, 54,542 non-Hispanic White individuals with hematological measures
were included in the analysis.
2.4.3.2 Womens Health Initiative (WHI)
WHI originally enrolled 161,808 women aged 50-79 between 1993 and 1998 at 40 cen-
ters across the US, including both a clinical trial (including three trials for hormone therapy,
dietary modification, and calcium/vitamin D) and an observational study arm (Anderson
et al., 1998). WHI recruited a socio-demographically diverse population representative of
US women in this age range. Two WHI extension studies conducted additional follow-up
on consenting women from 2005-2010 and 2010-2015. Genotyping was available on some
WHI participants through the WHI SNP Health Association Resource (SHARe) resource,
which used the Affymetrix 6.0 array („ 906,600 SNPs, 946,000 copy number variation
probes) and on other participants through the MEGA array (Wojcik et al., 2019). Imputa-
tion and association analysis was performed separately in individuals with Affymetrix only,
MEGA only, and both Affymetrix and MEGA data. For variants with both Affymetrix and
MEGA genotypes available, MEGA genotypes were used. In total, 18,100 self-reported
white women with hematological phenotypes were included. All WHI subcohorts were
imputed to 1000 Genomes Phase 3. Six sub-cohorts from the WHI study were included in
the meta-analysis and phenotypes were not collected uniformly across the cohorts. Sam-
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ple size information for each phenotype is contained in Supplementary Table 8 (bioRxiv
https://doi.org/10.1101/2021.02.23.432444).
2.4.3.3 Atherosclerosis Risk in Communities Study (ARIC)
The ARIC study was initiated in 1987 and recruited participants age 45-64 years from
4 field centers (Forsyth County, NC; Jackson, MS; northwestern suburbs of Minneapolis,
MN; Washington County, MD) to study cardiovascular disease and its risk factors (The ARIC
Investigators, 1989), including the participants of self-reported European ancestry included
here. Standardized physical examinations and interviewer-administered questionnaires were
conducted at baseline (1987-89), three triennial follow-up examinations, a fifth examination
in 2011-2013, a sixth exam in 2016-2017 and a seventh exam in 2018-2019. Genotyping
was performed through the CARe consortium Affymetrix 6.0 array (Musunuru et al., 2010).
ARIC European American genotype data were imputed to Haplotype Reference Consortium
(HRC) (McCarthy et al., 2016). In total, 9,345 European ancestry participants with hemato-
logical phenotypes were included in the analysis. All phenotypes were adjusted for study site,
age, age squared, sex, and top ten PCs and were inverse normalized.
2.4.3.4 Mount Sinai BioMe Biobank (BioMe)
The Mount Sinai BioMe Biobank, founded in September 2007, is an ongoing, broadly
consented EHR-linked bio- and data repository that enrolls participants non-selectively from
the Mount Sinai Medical Center patient population. The BioMe Biobank draws from a pop-
ulation of over 70,000 inpatient and 800,000 outpatient visits annually from over 30 broadly
selected clinical sites of the Mount Sinai Medical Center (MSMC). As of September 2020,
BioMe has enrolled more than 50,000 patients that represent a broad racial, ethnic and so-
cioeconomic diversity with a distinct and population-specific disease burden, characteristic
of the communities served by Mount Sinai Hospital. BioMe participants are predominantly
of African (AA, 24%), Hispanic/Latino (HL, 35%), European (EA, 32%), and other ances-
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try (OA, 10%). All blood cell phenotype data, as well as demographic variables, were ex-
tracted from the patients EHRs. Genotyping was performed using the Illumina GSA array („
640,000 variants) and genotype data were imputed using the “1000G Phase 3 v5” reference
panel. In total, 8,455 European ancestry participants with hematological phenotypes were
included in the analysis. All phenotypes were adjusted for study site, age, age squared, sex,
and top ten PCs and were inverse normalized. The BioMe Biobank Program operates under
a Mount Sinai Institutional Review Board-approved research protocol. All study participants
provided written informed consent.
2.4.4 Conditional Analysis
For each statistically significant TWAS gene-trait association, the effect of predicted
gene expression was conditioned on a set of previously reported GWAS sentinel variants
from Vuckovic et al. (2020) meeting the following criteria: 1) the sentinel variant fell within
a 1 Mb region of the TWAS gene, 2) the trait with which the GWAS variant was associated
matched the TWAS analytical trait or was within the same trait category as the analytical
trait (platelets, red blood cell indices [hematocrit, hemoglobin, mean corpuscular volume, red
blood cell count, red blood cell distribution width], white blood cell indices [white blood cell
count, neutrophils, monocytes, lymphocytes]), and 3) the GWAS variant met an imputation
quality threshold of R2 ą 0.3. We used a modified version of the cpgen R package (see
cpgen Methods) to perform the conditional analysis, accounting for a PLINK KING-robust
kinship matrix (Manichaikul et al., 2010), which used only genotyped variants and excluded
those with minor allele frequency less than 5% and those missing more than 1% of SNPs.
2.4.5 Meta-analysis and replication with ARIC, WHI, BioMe
In order to replicate the conditionally significant gene-trait association, we tested each
association via a meta-analysis of the ARIC, WHI, and BioMe cohorts. As described above,
PrediXcan was used to facilitate gene expression imputation and association in each cohort
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separately, and the meta-analysis association test was conducted using METAL (Willer et al.,
2010).
Replication of the GERA significant gene-trait associations was performed using meta-
analyzed TWAS results from ARIC, WHI, and BioMe. Seventeen gene-trait associations
remained statistically significant after conditional analysis; for this set of genes, we defined
a Bonferroni-corrected statistically significant replication threshold at p ă 2.94 ˆ 10´3. For
the fine-mapping analysis, statistical significance of replicated genes was qualified based on
two different thresholds – a stringent threshold Bonferroni-corrected for all 239 statistically
significant TWAS gene-trait associations at p ă 2.09ˆ 10´4, and a more lenient threshold at
p ă 0.05.
2.4.6 FOCUS
We used the Fine-mapping Of CaUsal gene Sets (FOCUS; Mancuso et al. (2019)) soft-
ware to fine-map TWAS statistics at genomic risk regions. As input, we used GWAS sum-
mary data from GERA along with eQTL weights from PredictDB Depression Genes and
Networks whole blood data, and the European LD reference panel from 1000 Genomes Phase
3. The software outputs a credible set of genes at each locus which can be used to explain
observed genomic risk.
2.4.7 Fine-mapping Loci and Locus Categories
Fine-mapping loci refers to fine-mapping analysis of trait-specific genomic locations that
contain, and are centered at, sentinel TWAS genes. That is, we take the set of trait-specific
statistically significant TWAS genes, select the most significant gene in the set (the sentinel
gene), and assign it to a locus along with any other statistically significant TWAS genes
within a 1 Mb window of the sentinel gene. We then select the next most significant TWAS
gene which has not yet been assigned to a locus and continue in this fashion until all statisti-
cally significant TWAS genes have been assigned to a locus.
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We define locus categories based on whether the locus contains a single gene or multiple
genes and whether at least one gene within the locus replicates in TWAS meta-analysis at
either a lenient or strict threshold. Thus, locus categories are defined as follows: 1 = single
gene locus, strict replication (p ă 2.09ˆ 10´4); 2 = single gene locus, replication (p ă 0.05); 3
= single gene locus, no replication; 4 = multi gene locus, strict replication (p ă 2.09ˆ 10´4); 5
= multi gene locus, replication (p ă 0.05); 6 = multi gene locus, no replication.
2.4.8 R Shiny
We use R’s convenient Shiny package (version 1.5.0, implemented in R 4.0.3) to produce
the web application which displays our GERA TWAS results. The IdeogramTrack (https:
//rdrr.io/bioc/Gviz/man/IdeogramTrack-class.html) uses Genome Ref-
erence Consortium Human Build 37 (GRCh37) and UCSC cytogentic bands from http:
//hgdownload.cse.ucsc.edu/goldenpath/hg19/database/. All GERA
TWAS results were produced using PrediXcan as described above.
For GWAS results, GERA phenotypes (log10 transformed for WBC subtypes) were based
on inverse normalized residuals and adjusted for sex, age, age-squared, and the first 10 ge-
netic principal components; analysis was done with Bolt LMM as implemented in rvtests
(Zhan et al., 2016), as used in the meta-analyses reported in (Vuckovic et al., 2020). We
excluded those without a valid date of blood cell count measurement, with age less than
18 years, or with discordant genotypic and phenotypic sex, as well as those with no blood
cell trait data. The cohort also has longitudinal data; we preferentially selected the first visit
with complete data for all measures. If no visit had complete data, we used the first available
visit. We also excluded extreme blood cell measures: WBC ą 200x109 cells/L, HGB ą 20
g/dL, HCT ą 60%, and PLT ą 1000x109 cells/L. For WBC subtypes, we analyzed log10-
transformed absolute counts obtained by multiplying relative counts with total WBC count.
Custom Axiom arrays used for GERA genotyping have been previously described (Hoffmann
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et al., 2011b,a), as has genotype calling with apt-probeset-genotype and generation of PCs
using EIGENSOFT4.2 (Banda et al., 2015).
GERA conditional analysis results were produced using cpgen as described below.
Known GWAS sentinel variants were obtained from (Vuckovic et al., 2020). Model weights
and model variants were taken from our primary DGN reference panel from PredictDB
(or secondary reference panels GWB, GTL, or MSA from PredictDB). Correlation of pre-
dicted expression among genes at the locus was calculated using R’s cor() function, and
LD among variants was computed using plink --r2 (https://zzz.bwh.harvard.
edu/plink/ld.shtml). We used ggplot2() to produce all figures, except the network
visualization used visNetwork(). The DT package (https://www.rdocumentation.
org/packages/DT/versions/0.16) was used to produce all of the tables in the appli-
cation.
2.4.9 cpgen
We used the R package cpgen to perform conditional analysis of TWAS-significant
genes, while accounting for a KING kinship matrix. However, cpgen is designed in such a
way that it performs eigenvalue decomposition on the cohort sample for every function call.
Since we had 239 TWAS-significant associations, this would have required eigenvalue decom-
position on a sample of N « 55, 000 for each of those 239 associations, a computationally
burdensome calculation. Thus, we slightly modified the cpgen script. Specifically, we com-
puted the eigenvalue decomposition on the GERA sample outside of the cpgen script (for
each phenotype), and then subsequently loaded the appropriate eigenvectors and eigenvalues
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CHAPTER 3: TWAS INTEGRATED WITH R SHINY
3.1 Introduction
As discussed in Chapter 1, the interpretation of TWAS results is not always straightfor-
ward and can be quite challenging, especially for large-scale analyses such as that we have
performed in GERA (Chapter 2). Care must be taken to interpret TWAS results in context
(e.g. alongside information known from other ’omics studies such as GWAS), understand
how multiple TWAS signals at a given locus may be affected by correlated gene expression
and/or the sharing of predictive model variants, and evaluate how fine-mapping results either
clarify the most likely causal genes, or may be confounded by some of the same challenges as
the original TWAS analysis (as described in Chapter 1).
Thus, in order to facilitate the interpretation of TWAS findings, in this chapter we in-
troduce R Shiny and present an R Shiny application that we have designed to interactively
visualize our GERA TWAS results from Chapter 2 (http://shiny.bios.unc.edu/gera-twas/). We
discuss, in detail, the key features of the R Shiny application, and show how we have used it
to quickly interpret very complex TWAS loci in the context of prior knowledge from GWAS.
We conclude with a corresponding R package, called LocusXcanR, which is publicly avail-
able on my GitHub page (https://github.com/amanda-tapia) and available soon on CRAN
for other researchers to visualize their own TWAS results. We further present the primary
features and documentation of LocusXcanR along with its customizable user interface.
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3.2 R Shiny
R Shiny (Chang et al., 2017) is an open source R package that makes it incredibly easy
to design interactive web applications and dynamic dashboards using R, with an elegant, flex-
ible, and powerful framework for building such applications. Although Shiny apps can be
extended and enhanced with CSS themes, htmlwidgets, and JavaScript actions, prior knowl-
edge of these programming languages or web development is not required. Additionally,
Shiny applications (Shiny apps) can be hosted in various ways, for example, on a standalone
webpage, embedded in an R Markdown document or constructed as a dashboard.
A unique component of the Shiny app framework is in its reactive programming, which
consists of three different kinds of objects: reactive sources, reactive conductors, and reactive
endpoints. In a Shiny app, the source is typically user input through a browser interface. For
example, user actions such as selecting an item, typing input, or clicking a button will set
values that are designated as reactive sources. A reactive endpoint is usually something that
appears in the user’s browser window, such as a figure or a table. The most simple of Shiny
app structures may contain only one source and one endpoint, where the reactive source is
accessible through the input object, and the reactive endpoint is accessible through the output
object. However, a reactive source can be connected to multiple endpoints, and vice versa, in
more complex configurations.
Reactive conductors are an additional type of reactive component that can be placed in
between reactive sources and reactive endpoints. Whereas reactive sources can only have
dependents and reactive endpoints can only be dependents in a reactive environment, reactive
conductors can both be a dependent and have dependents and are useful for encapsulating
slow or computationally expensive operations that would, for example, otherwise have to be
called within the program multiple times. It should also be noted that traditional programs
with an interactive user interface might typically involve setting up event handlers and writ-
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ing code to read values and transfer data; however, R Shiny performs these tasks behind the
scenes, allowing the user to write code that looks like regular R code.
In addition to reactive programming, Shiny apps consist of two primary components – a
server and a user interface (UI). These components can be constructed in either a single file
(i.e. the code for both the server and UI are contained in one file) or a multiple file (i.e. the
code for the server is in a separate file from the UI code) configuration. These configurations
functionally produce the same Shiny app, but the multiple file configuration is generally
preferred, especially for larger applications, as it usually eases code management. However,
for smaller Shiny apps, the single file configuration is likely more efficient.
Several options also exist for deploying Shiny apps. Namely, they can be run locally,
pointing to a specified home directory; they can be hosted and run on an organization’s inter-
nal server; or they can be deployed on shinyapps.io, hosted by RStudio. Together, the server,
the UI, and the reactive programming create a unique and simple framework for displaying
large-scale, interactive visualizations and tables within a webpage.
3.2.1 R Shiny Application Features in GERA TWAS
Upon first rendering the Shiny app for our GERA analysis, users are presented with de-
tails of the specific analysis that has been performed, as well as any additional definitions
and information that assist in understanding and interpreting the remainder of the presented
results (Figure 3.1). One of the most useful features of the application that we have designed
for GERA TWAS is the drop-down menu which allows users to quickly render information
related to a specific locus of interest. In our particular study (Chapter 2), we have 120 trait-
specific, distinct regions across the genome containing TWAS significant genes which we
are interested in exploring further. Thus, the locus-selection menu allows us to quickly and
efficiently visualize a large set of TWAS significant results in context. Further, the details
listed in the locus-selection menu offer a brief description of the locus characteristics them-
selves, displaying the locus number, chromosome, locus start position, locus stop position,
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Figure 3.1: R Shiny application header details. The application features a brief overview of
the analysis, a drop-down menu for selecting a locus to view, and an IdeogramTrack
specifying the chromosome and the position of the locus on the chromosome. The
locus-selection menu displays the following [locus # : chr : locus start position, locus stop
position : index gene : phenotype].
locus index gene, and associated phenotype. An IdeogramTrack additionally displays the full
chromosome, as well as the position of the locus on the chromosome (Figure 3.1).
The first primary figure in the application (Figure 3.2) displays a mirror plot of TWAS re-
sults in the top panel and GWAS results in the bottom panel for this locus. As we mentioned
in Chapter 1, interpreting TWAS results in the context of previously reported information
from other ’omics studies, such as GWAS, is critically important. Figure 3.2 allows us to
quickly gain an understanding of how and whether our TWAS results correspond to results
previously reported by GWAS. Here, the index TWAS gene (GLT8D1) has not been previ-
ously reported in the GWAS catalog as the assigned gene (often based on physical proxim-
ity) for a single-variant signal associated with the phenotype category; other non-significant
TWAS genes at the locus have been assigned to one or more GWAS variants in previous
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Figure 3.2: TWAS-GWAS mirror plot of genes and variants within the locus. Top figure
displays TWAS significant genes and any additional non-significant genes reported from
GWAS, bottom figure displays GWAS variants. In the TWAS plot, “reported in GWAS”
means that the GERA TWAS gene was reported in the GWAS catalog as the assigned gene
for a single-variant signal associated with the phenotype category, often based on physical
proximity. In the GWAS plot, “reported in GWAS” means that the GERA GWAS variant was
reported in the GWAS catalog as a single-variant signal associated with the phenotype
category. Marginal TWAS displays results of gene-trait associations (shown here).
Conditional TWAS displays results of gene-trait associations, conditional on reported GWAS
variants at the locus (not shown).
studies. We also observe very little GERA GWAS signal, as evidenced by only a few GERA
GWAS variants exceeding the genome-wide significance threshold of p ă 5 ˆ 10´8 (Figure
3.2, bottom panel dashed red line). Additionally, the application allows us to toggle between
marginal TWAS results and conditional TWAS results (not shown), in order to determine
whether any TWAS signal remains after conditioning on the known GWAS variants within
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Figure 3.3: R Shiny TWAS-GWAS LocusZoom mirror. Top panel displays predicted
expression correlation between index TWAS gene and other genes at the locus; color scale for
genes denotes the degree of predicted expression correlation with the index gene (given in the
legend). Bottom panel displays LD between the index SNP and other SNPs at the locus; color
scale for SNPs and solid lines denotes the degree of LD with the index SNP. Lines connect
genes to their predictive model variants. Dashed red line in the top panel denotes TWAS
p-value threshold = 4.37ˆ 10´7, and in bottom panel denotes GWAS p-value threshold =
5ˆ 10´8.
the locus. Understanding this relationship can provide evidence of a novel signal, if GWAS
sentinel variants have not been previously reported within the locus, as well as evidence of a
TWAS signal not fully captured by GWAS sentinel variants, if the conditional TWAS result
retains some residual signal (e.g. p ă 0.05).
Figure 3.3 provides a LocusZoom-like mirror plot for depicting predicted expression cor-
relation among the TWAS genes in GERA in the top panel, and the LD pattern (calculated in
GERA) among variants in the bottom panel. Specifically, the color scale for genes denotes the
degree of predicted expression correlation with the index gene (i.e. most significant TWAS
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Figure 3.4: R Shiny TWAS-GWAS limited LocusZoom mirror. Displaying Figure 3.3 but
highlighting the interactivity of the legend, showing that only genes, variants, and lines with
correlation greater than 0.6 may be selected, while those with lower correlations may be
turned off.
gene), and the color scale for SNPs and the solid lines denotes the degree of LD with the
index SNP (i.e. most significant GWAS variant), with solid lines connecting genes to their
predictive model variants. Aside from being able to quickly identify the relationships among
genes and their model variants, the full interactivity of this figure is one of its main features.
For example, specific items within the legend may be selected to highlight various compo-
nents of the plot; Figure 3.4 displays the same locus as in Figure 3.3, but depicts only those
genes and variants with correlation greater than 0.6, and removes any details with lower cor-
relation. Additionally, the user may further zoom into this specific region of the plot (Figure
3.5) to observe greater detail and the sharing of model variants among the displayed genes.
Yet another alternative to visualizing the information at this locus, and particularly highlight
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Figure 3.5: R Shiny TWAS-GWAS limited and zoomed in LocusZoom mirror. Displaying
Figure 3.3 but highlighting the interactivity of the legend and the plot itself. Only genes,
variants, and lines with correlation greater than 0.6 are displayed and the region is zoomed in
for a more detailed view.
the sharing of model variants among genes, is a network visualization (Figure 3.6). These
network visualizations allow us to easily identify the index gene (red star), observe any com-
plexity in the sharing of model variants, and also understand how the model weights (denoted
by line thickness) may or may not contribute to TWAS significance at any given locus. For
example, at this particular locus, GLT8D1 (the index gene) does not share any model variants
with the other genes at this locus, although it has a relatively high correlation with NT5DC2.
Only NT5DC2 and STAB1 share a single model variant. Additionally, we see that GLT8D1
contains the index variant (red triangle) in its predictive model as well as all other variants
in very high LD (red circles) with the index variant, whereas NT5DC2’s predictive model
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Figure 3.6: R Shiny network visualization. Sentinel TWAS gene is indicated by a red star, all
other genes are squares. Sentinel GWAS variant is indicated by a red triangle, all other
variants are circles. Color scale of all lines and shapes is based on correlation with the index
gene or index variant, similar to Figure 3.3. Line thickness corresponds to the model weight.
Solid line indicates a positive direction of effect and dashed line indicates a negative direction.
The size of each shape (star, square, triangle, circle) corresponds to the size of the
-log10(p-value).
contains only a few variants in marginally high LD (orange circles) with the index variant, but
has more variants with larger weights (i.e. thicker lines), as compared to GLT8D1.
Each of the remaining figures in the Shiny app has similar interactivity as that in Figure
3.3, with zoom-in capabilities, an interactive legend, and other plot features, yet they answer
different questions about the results. For example, Figure 3.7 displays the TWAS results
from our primary analysis (top panel) and the results of TWAS meta-analysis (bottom panel).
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Figure 3.7: R Shiny TWAS meta-analysis mirror plot. Top figure displays TWAS significant
genes and any additional non-significant genes reported from GWAS, bottom figure displays
TWAS meta-analysis results for the same genes. “Reported in GWAS” means that the TWAS
gene was reported in the GWAS catalog as the assigned gene for a single-variant signal
associated with the phenotype category, often based on physical proximity. Lenient and
stringent p-value thresholds are given by the orange and red dashed horizontal lines,
respectively.
This figure answers the question: Do our primary TWAS results replicate in meta-analysis,
either at a stringent, Bonferroni-corrected threshold or a more lenient p ă 0.05 threshold?
This can provide further evidence to support our TWAS result as a true signal, if it replicates
in meta-analysis, but does not necessarily rule it out as a true signal if it does not replicate
in meta-analysis. The latter is true because the meta-analysis sample size is much smaller
(ARIC N “ 9, 345, WHI N “ 18, 100, and BioMe N “ 8, 455) than the sample size of our
original discovery cohort (GERA N “ 54, 542). At this locus, GLT8D1 is right on the margin
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Figure 3.8: R Shiny primary TWAS / secondary TWAS mirror plot. DGN = Depression
Genes and Networks, GWB = GTEx whole blood, GTL = GTEx EBV transformed
lymphocytes, MSA = MESA monocytes; each represents a gene expression reference panel.
The figure in each tab (located across the top of the panel) displays a mirror plot of GERA
results using DGN reference panel versus GERA results using a secondary reference panel
(GWB, GTL, or MSA).
of replicating at p ă 0.05, but does not provide enough additional evidence in support of this
gene being a true signal.
In Figure 3.8, we compare TWAS results using our primary reference panel from De-
pression Genes and Networks whole blood (DGN, Battle et al. (2014), top panel) to TWAS
results using other reference panels such as Genotype Tissue Expression whole blood (GWB,
The GTEx Consortium (2017), shown in bottom panel). We see that a gene may appear in
both reference panels, or it may only appear in DGN. If the gene does appear in both refer-
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ence panels, and it exceeds the p-value threshold for TWAS significance in the secondary
reference panel, then it again provides additional evidence to support the gene as a true signal
in blood cell relevant tissues, in this case. However, at this locus, we observe that GLT8D1 is
not available (or was not predicted) in GWB. Of note are the additional tabs at the top of Fig-
ure 3.8, displaying “DGN vs. GWB”, “DGN vs GTL” and “DGN vs MSA” which allow us to
quickly toggle between each of the reference panels that we have analyzed in this study. Sim-
ilar to the other figures, the interactive legend also allows us to display all genes, only those
genes that are contained in both reference panels, or only those genes that are not contained in
both reference panels.
The remainder of the Shiny app contains detailed tables displaying the results presented
in the figures, as well as any additional information available from TWAS primary analysis,
previously reported GWAS results, TWAS meta-analysis, TWAS from different gene expres-
sion reference panels, and results from TWAS model training. Similar to the figures within
the application, the tables are also interactive. An example table of overall TWAS results
from primary and secondary reference panels within the locus is presented in Figure 3.9. The
“tabbed” feature at the top of the table [indicated by (1)] allows users to quickly view the full
set of TWAS results at a locus for various gene expression reference panels (or any other type
of relevant data of interest). The search box [indicated by (2)] is convenient for searching
within any field of the table to look up, for example, the results of a particular gene or trait.
Finally, additional entries within the table may be viewed swiftly via the page navigation
buttons [indicated by (3)] affixed to the bottom of every table. Additional tables, with sup-
plementary relevant information and similar interactively as shown in Figure 3.9, are also
available within the R Shiny application, though are not depicted here.
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Figure 3.9: R Shiny TWAS detailed results table. 1) Feature which allows users to tab through results of different gene expression
reference panels (reference panels are denoted as: DGN = DGN whole blood, GWB = GTEx whole blood, GTL = GTEx EBV
transformed lymphocytes, MSA = MESA monocytes. 2) Search box to lookup a value anywhere in the table. 3) Page navigation
buttons to view additional table entries.
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The R Shiny application together with the specific figures and tables that we have pre-
sented enables us to efficiently and interactively visualize the TWAS results from our primary
analysis, as well as a wealth of information available from GWAS, conditional analyses, and
other TWAS analyses. Each of the figures and tables within the application is designed to
address one or more of the many challenges inherent to the interpretation of TWAS results (as
highlighted in Chapter 1), including incorporating knowledge of previously reported GWAS
sentinel variants (and the genes implicated by those variants), understanding the relation-
ship among genes at the locus via their predicted expression correlation, and recognizing
the influence that the LD pattern among variants used for gene expression prediction and the
sharing of model variants has on TWAS results. Thus, once researchers become familiar with
the information presented within the Shiny app, another main advantage that it offers is the
rapid identification of a locus’s predominant features via the processing and visualizing of an
enormous amount of data, a challenge that would be difficult to otherwise overcome.
3.2.2 R Package for R Shiny TWAS Application
Alongside the LocusXcanR Shiny app that we developed to present details of our
GERA TWAS results from Chapter 2, we have also created a LocusXcanR R package (cur-
rently available on GitHub [https://github.com/amanda-tapia] and soon to be available on
CRAN). The R package provides a framework for other researchers to import and visualize
their own TWAS results in the context of other ’omics information.
A vignette documenting the LocusXcanR package and describing its use is available
within the package itself and is presented in Appendix A. The vignette features a detailed
description of the LocusXcanR function, along with its required and optional parameters.
Further, the application runs on an extensive amount and variety of data, and thus, several
data pre-processing steps are required. A complete description of each required and optional
dataset is also contained within the vignette, along with a summary of each dataset’s purpose,
its variable name descriptions, and example data.
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Finally, the vignette additionally contains information directing the user to an example R
script, and it provides further recommendations about publishing an R shiny application. The
vignette concludes with frequently asked questions regarding getting started with R Shiny,
understanding LocusXcanR’s parameters, and troubleshooting data pre-processing steps.
3.3 Conclusion
With our GERA TWAS results (Chapter 2), we demonstrated the value and importance
of visualizing TWAS results in the context of previously reported GWAS information in order
to effectively interpret these results. TWAS results, namely p-values, should not be simply
interpreted at face value. In this chapter, we introduce our R Shiny app, LocusXcanR, and
show how it provides an interactive and user-friendly platform for gaining a broader under-
standing of the complexity and the wealth of information available at a single TWAS locus; it
additionally allows the user to rapidly identify key locus features at scale.
Given the value of and the knowledge gained from interpreting TWAS results alongside
other ’omics information, we encourage other researchers to utilize tools, such as R Shiny,
to interpret their results in context as well, before drawing hasty conclusions from initial
TWAS findings. We additionally emphasize that, once the Shiny app is created, the user
interface is very user-friendly for statisticians, researchers with less programming and big
data experience, and even clinicians who may be interested in exploring the data further,
without having to manage a wealth of genetic information scattered across multiple sources.
We hope that providing our Shiny app as a LocusXcanR R package will further facilitate the
practice of interpreting TWAS results together with other ’omics information.
65
CHAPTER 4: ARIC METABOLOME-WIDE ASSOCIATION STUDY
4.1 Introduction
Transcripts, proteins, and metabolites (i.e. multi-omics data) are all of interest as poten-
tial disease risk factors, and as we have seen in previous chapters, gene expression levels
can provide biological insights into GWAS-discovered associations. Similarly, proteins and
metabolites may serve as potential mediators of the signals identified by GWAS as well. Un-
fortunately, sample sizes for high throughput multi-omics datasets have lagged behind genetic
datasets, often due to expense and lack of tissue availability. However, in recent years, the
high throughput profiling of gene expression (Dykstra-Aiello et al., 2016; Zeller et al., 2017;
He et al., 2018; Huang et al., 2018; Ng et al., 2017; Hoffman et al., 2019; Fromer et al., 2016;
Liu et al., 2017; Mogil et al., 2018; Shang et al., 2020; The GTEx Consortium, 2020), protein
levels (Ngo et al., 2016; Jacob et al., 2018; Zanini et al., 2020; Williams et al., 2019; Sun
et al., 2018), and metabolite measurements (Shah et al., 2012; RuizCanela et al., 2017; Dang
et al., 2018; Peng et al., 2020) have been used successfully in the study of chronic diseases.
Thus, it is hypothesized that these transcripts, proteins, and metabolites together can further
our understanding of the broad regions of association identified by GWAS, by linking them
with the biologically mechanistic insights that multi-omics data can provide. In the remainder
of this chapter, we specifically focus on metabolites, discuss the methods used for their identi-




Metabolites, such as sugars, lipids, amino acids, and alkaloids, are the small molecule
endpoints of many biological processes. They serve various functions within cells, bioflu-
ids, tissues or organisms including fuel, structure, signaling, excitatory and inhibitory effects
on enzymes, etc (EMBL-EBI, 2021). Additionally, metabolites are influenced by genetics,
the microbiome, drug exposures, other metabolites, and many other environmental factors
(EMBL-EBI, 2021). The collection of these small molecules and their interactions within a
biological system are known as the metabolome. Thus, metabolomics is the large-scale study
of these small molecules (the substrates and products of metabolism), similar to the way in
which genomics is the study of DNA and genetic information within a cell, and transcrip-
tomics is the study of RNA and differences in mRNA expression.
The study of these small molecules has the potential to offer profound biological insights
because metabolite concentrations directly reflect the underlying biochemical activity and
state of cells and tissues, and thus, provide a direct representation of the molecular phenotype.
Additionally, given the non-invasive nature of metabolomics, it is an ideal target for phar-
maceutical and preventive healthcare industries, for example. Through biomarker discovery
and personalized medicine, metabolomics can not only inform population-based approaches
to healthcare, but could potentially be used to track our own personalized metabolome to
identify disease states much earlier and improve treatment strategies (Ford et al., 2020).
Metabolomics technologies such as nuclear magnetic resonance (NMR) spectroscopy
(EMBL-EBI, 2020d) and liquid chromatography-mass spectrometry (LC-MS) (EMBL-EBI,
2020c) are used to perform a comprehensive analysis (i.e. identification and quantification) of
metabolites, and this metabolite profiling is typically performed using two main approaches
– targeted or untargeted (EMBL-EBI, 2020b). Targeted and semi-targeted approaches/plat-
forms assess a subset of biochemically well-characterized metabolites in a tissue and tend
to address a specific biological question. This approach focuses on accurate identification
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and quantification of a defined set of metabolites in biological samples which are typically
predetermined by the scientific question, and are often NMR-based. NMR-based platforms
tend to have very high reproducibility, require minimal sample preparation, have fast sample
analysis times, and benefit from low cost per sample. However, compared to MS platforms,
NMR approaches have low sensitivity, a lower number of detectable metabolites, and require
more expensive instruments that occupy more physical space (EMBL-EBI, 2020a).
Untargeted platforms attempt to measure as many metabolites as possible, including
those with unknown identity, from a range of biological samples without any (intended) bias,
and are often LC-MS based. MS-based platforms tend to have high sensitivity, a high number
of detectable metabolites, and less expensive instrument costs. However, compared to NMR
approaches, MS-based methods do not perform as well in terms of reproducibility, require
tissue extraction and more complex sample preparation, and have a higher cost per sample
(EMBL-EBI, 2020a).
4.3 Metabolome-wide Association Study
As previously discussed (Chapter 1), TWAS methods were developed to use reference
eQTL datasets, such as those from GTEx (The GTEx Consortium, 2020) or DGN (Battle
et al., 2014), to select genetic variants which, in aggregate, associate with tissue-specific
gene expression. The weights based on variant associations with a transcript are then applied
to cohorts which contain genotype data, but not gene expression data. Transcripts whose
levels can be confidently imputed from genetic variants are then assessed for phenotype as-
sociations. Similar to gene expression levels, serum levels of many metabolites are heritable
(Kiddle et al., 2015; Rhee et al., 2016), and metabolomics GWAS studies have identified
metabolite quantitative trait loci (mQTL) associated with serum and plasma metabolites (Shin
et al., 2014; Long et al., 2017; Lotta et al., 2020) as well as metabolites in urine (Schlosser
et al., 2020), salivary metabolites (Nag et al., 2020), cerebrospinal fluid metabolites (Panyard
et al., 2020), steroid hormone levels (Pott et al., 2019), and many others. This suggests that
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metabolites could be predicted using genetic data, in a similar manner in which transcripts are
predicted in TWAS. However, similar to TWAS analyses where most reference eQTL datasets
include predominantly European American individuals (The GTEx Consortium, 2020; Battle
et al., 2014), the reference mQTL dataset must be carefully considered. As evidenced by a
metabolomics GWAS study of circulating metabolites in the Hispanic Community Health
Study/Study of Latinos (HCHS/SOL; Feofanova et al. (2020)), ancestry-specific signals
which are rare in European Americans can exist. These differences in circulating metabolites
(as well as differences in SNP allele frequencies) in different populations may be attributable
to a variety of genetic and environmental factors. While the genetic influences are more im-
portant for our purposes, in either case, these cross-population differences can limit the pre-
dictive power of a metabolome-wide association study in non-European ancestry populations,
if a European population is used as the reference.
In this chapter, we aim to adapt the conceptually similar TWAS approach to create a
novel metabolome-wide association study approach (MWAS) that uses genetic variants to
infer heritable metabolite levels, instead of an mRNA transcript. We use the high through-
put metabolomics data, including 245 named metabolites (post quality control checks), in
European Americans (EAs, N = 1,553) and African Americans (AAs, N = 2,479) from the
Atherosclerosis Risk in Communities Study (ARIC, The ARIC Investigators (1989)) to con-
struct a MWAS reference panel, and we then apply the MWAS approach to the study of hema-
tological traits in EA and AA populations, the latter of which are traditionally underrepre-
sented in ’omics research.
4.4 Results
In our preliminary method, we divide the ARIC sample into thirds. We then run metabo-
lite GWAS in one-third of the sample to select nominally significant variants associated with
metabolites. Then we train elastic net models in one-third of the sample, using the nominally
significant variants identified in metabolite GWAS; we do this in ARIC EAs and AAs sep-
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arately. We use the remaining one-third of the sample to assess the performance of EA and
AA derived weights by computing the correlation between observed and predicted metabolite
measures. We also compare the performance of weights derived with metabolomics data in
EAs to those derived in AAs.
4.4.1 Trait-Metabolite Association Analysis
In order to assess the direct relationship between each hematological phenotype and
observed metabolite pair, we first performed a simple linear regression analysis on ARIC
EAs and AAs separately. We analyzed 245 metabolites and 7 phenotypes (i.e. 1,715 trait-
metabolite pairs) and found 211 (12.3%) statistically significant trait-metabolite associations
(p ă 0.05{1715 “ 2.92 ˆ 10´5) in the EA group and 176 (10.3%) statistically significant
trait-metabolite associations in the AA group (Table 4.1).
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Table 4.1: Summary of ARIC EA and AA trait-observed metabolite association analysis.
European African
non-significant p ă 0.05 p ă 2.92ˆ 10´5 non-significant p ă 0.05 p ă 2.92ˆ 10´5
Hematocrit 122 91 32 115 91 39
Hemoglobin 114 86 45 122 76 47
Lymphocyte 156 73 16 174 63 8
Monocyte 176 59 10 158 81 6
Neutrophil 125 75 45 131 88 26
Platelet 194 41 10 158 78 9
White blood count 92 100 53 110 94 41
Total 979 525 211 968 571 176
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Figure 4.1: Distribution of EA (A) and AA (B) phenotype-observed metabolite association
-log10 p-values, by phenotype. Dashed vertical red line indicates Bonferroni-corrected
statistical significance (p ă 2.92ˆ 10´5).
We see the highest number of significant associations among metabolites with hematocrit,
hemoglobin, neutrophils, and WBC; this pattern is similar for both EA and AA groups (Table
4.1). Metabolite associations with these same 4 phenotypes tend to have the most significant
p-values (Figure 4.1A and 4.1B), and metabolites associated with platelets also have very
significant p-values; this pattern is similar across ancestry groups. Furthermore, we note
that hematocrit, hemoglobin, WBC, and platelets also have the largest sample sizes in this
analysis (Table 4.2)
Additionally, among the 1,715 trait-metabolite pairs for each ancestry group, 1,333
(77.7%) have the same direction of effect, when comparing EAs to AAs (Figure 4.2A); all of
the trait-metabolite associations that are statistically significant in both ancestry groups (108
associations) have the same direction of effect when comparing EAs to AAs (Figure 4.2B).
Among the total number of EA significant metabolites (N = 211):
72










White blood count 1,467 1,581
Figure 4.2: Comparison of EA and AA phenotype-observed metabolite association -log10
p-values, by phenotype. (A) All trait-metabolite associations. Dashed vertical and horizontal
red lines indicate Bonferroni-corrected statistical significance (p ă 2.92ˆ 10´5). (B)
Statistically significant trait-metabolite associations with EA and AA estimates having the
same direction of effect.
• 108 (51%) have the same direction of effect and are statistically significant (p ă 2.92ˆ
10´5) in the AA group;
• 81 (38%) have the same direction of effect and are nominally significant (p ă 0.05) in
the AA group;
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• 19 (9%) have the same direction of effect in the AA group but are not significant; and
• 3 (1%) do not have the same direction of effect in the AA group and are not significant;
Among the total number of AA significant metabolites (N = 176):
• 108 (61%) have the same direction of effect and are statistically significant (p ă 2.92ˆ
10´5) in the EA group;
• 50 (28%) have the same direction of effect and are nominally significant (p ă 0.05) in
the EA group;
• 14 (8%) have the same direction of effect in the EA group but are not significant; and
• 4 (2%) do not have the same direction of effect in the EA group and are not significant;
Figure 4.2B also shows some consistency between the EA and AA results. The most
significant associations in both groups tend to be for:
• Hematocrit with azelate, undecanedioate, suberate, and sebacate;
• Hemoglobin with azelate, undecanedioate, suberate, and sebacate; and
• Platelets with hypoxanthine and guanosine.
Associations with WBCs are slightly less prominent, but appear for phenylalanylleucine,
lactate, ocresolsulfate, and gammaglutamylthreonine. Finally, the EA group contained 8
metabolites with 5 or more statistically significant trait associations (lactate, ocresolsulfate,
gammaglutamylthreonine, mannose, ornithine, phenylalanylleucine, phenylalanylphenylala-
nine, xanthine); the AA group had 4 metabolites with 5 or more statistically significant trait
associations (lactate, gammaglutamylthreonine, phenylalanylleucine, pyroglutamylglycine).
To determine consistency in ARIC results in another independent study, we performed a
similar trait-metabolite association analysis on observed phenotypes and metabolites in HCH-
S/SOL (LaVange et al., 2010). In HCHS/SOL trait-metabolite pairs that match to ARIC, we
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Figure 4.3: HCHS/SOL distribution of trait-observed metabolite associations by phenotype.
Dashed vertical red line indicates Bonferroni-corrected statistical significance
(p ă 2.92ˆ 10´5).
see a similar pattern in significant associations compared to ARIC. Specifically, the highest
number of significant associations in HCHS/SOL is for hematocrit, hemoglobin, and WBCs
(Table 4.3), and the distribution of p-values in HCHS/SOL is also similar to ARIC, with the
Table 4.3: HCHS/SOL trait-observed metabolite associations by significance level and
phenotype.
significance
N non-significant p ă 0.05 p ă 2.92ˆ 10´5
Hematocrit 3,879 71 83 42
Hemoglobin 3,879 66 64 66
Lymphocyte 3,656 110 57 29
Monocyte 3,656 94 73 29
Neutrophil 3,656 90 67 39
Platelet 3,874 120 51 25
White blood count 3,656 82 67 47
Total 633 462 277
most significant associations observed for platelets (Figure 4.3). Furthermore, we find consis-
tencies between ARIC and HCHS/SOL upon direct comparison of trait-metabolite matched
p-values and estimates of the direction of the effect (Figure 4.4). Among the 1,372 total as-
sociations, 948 (69%) of the estimates for ARIC EAs have the same direction effect when
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Figure 4.4: ARIC trait-observed metabolite associations versus HCHS/SOL trait-observed
metabolite associations, by phenotype and direction of effect. HCHS/SOL compared to ARIC
EAs (A) and ARIC AAs (B). Dashed vertical and horizontal red lines indicate
Bonferroni-corrected statistical significance (p ă 2.92ˆ 10´5).
compared to HCHS/SOL, and 345 (36%) of these have at least some marginal significance
in both HCHS/SOL and ARIC EAs. For AAs, 990 (72%) of the 1,372 association estimates
have the same direction of effect as HCHS/SOL, and 355 (36%) of these have at least some
marginal significance in both HCHS/SOL and ARIC AAs (Table 4.4).
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Table 4.4: HCHS/SOL trait-observed metabolite associations by direction of effect and significance level compared to ARIC EA and
ARIC AA trait-observed metabolite associations.
ARIC EA ARIC AA
HCHS/SOL not significant p ă 0.05 p ă 2.92ˆ 10´5 not significant p ă 0.05 p ă 2.92ˆ 10´5
Same direction of effect
not significant 253 97 27 255 120 16
p ă 0.05 159 127 46 169 152 36
p ă 2.92ˆ 10´5 67 94 78 75 104 63
Total 479 318 151 499 376 115
Different direction of effect
not significant 197 48 11 178 51 13
p ă 0.05 97 27 6 77 22 6
p ă 2.92ˆ 10´5 21 14 3 22 9 4
Total 315 89 20 277 82 2377
Figure 4.5: ARIC trait-observed metabolite significant associations versus HCHS/SOL
trait-observed metabolite significant associations with the same direction of effect, by
phenotype. HCHS/SOL compared to ARIC EAs (A) and ARIC AAs (B).
The most significant metabolites are congruous across cohorts as well (Figure 4.5).
Among the associations that are statistically significant in both ARIC and HCHS/SOL and
have the same direction of effect, we identify the following most prominent associations:
• Platelets with guanosine, hypoxanthine, and serotonin;
• White blood cell count with lactate, ocresolsulfate, and mannose; and
• Neutrophils with lactate and ocresolsulfate.
In a trans-ethnic meta-analysis of ARIC EA, ARIC AA, and HCHS/SOL observed
metabolite associations with hematological measures (see Methods 4.6.2), we found that
among the 1,372 matched trait-metabolite pairs, 431 associations (31%) were statistically sig-
nificant (p ă 2.92ˆ 10´5) and had the same direction of effect (Table 4.5). An additional 370
associations (27%) were nominally significant (p ă 0.05) with the same direction of effect.
Given our trait-specific results, as expected, we saw that the highest number of metabolites
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Table 4.5: Meta-analysis of ARIC EA, ARIC AA, and HCHS/SOL trait-observed metabolite
associations by direction of effect and level of significance.
significance
non-significant p ă 0.05 p ă 2.92ˆ 10´5 Total
Direction of effect
Different 288 69 15 372
Same 199 370 431 1,000
Total 487 439 446 1,372
Table 4.6: Meta-analysis of ARIC EA, ARIC AA, and HCHS/SOL trait-observed metabolite
associations by phenotype and level of significance.
significance
N non-significant p ă 0.05 p ă 2.92ˆ 10´5 Total
Hematocrit 6,927 49 65 82 196
Hemoglobin 6,927 39 61 96 196
Lymphocyte 6,258 102 48 46 196
Monocyte 6,231 76 80 40 196
Neutrophil 6,250 63 64 69 196
Platelet 6,914 107 60 29 196
White blood count 6,704 51 61 84 196
Total 487 439 446 1,372
were significantly associated with hemoglobin, hematocrit, and white blood cell count (Table
4.6). However, the most significant associations were for platelet counts with hypoxanthine
(p “ 3.60ˆ 10´168) and guanosine (p “ 9.37ˆ 10´173) (Figure 4.6), which is in line with the
associations highlighted above.
Upon further exploration, we find that hypoxanthine is known to be biologically lo-
cated in blood (Kaya et al., 2006; Wishart et al., 2018), particularly within platelets (Wishart
et al., 2018); guanosine is also known to be biologically located in blood (Hartwick et al.,
1979; Wishart et al., 2018). In addition, hypoxanthine and phosphoribosyl pyrophosphate
can be biosynthesized from inosinic acid through the action of the enzyme hypoxanthine-
guanine phosphoribosyltransferase (HGPRT) (HMDB, 2021). HGPRT is an enzyme en-
coded in humans by the HPRT1 gene, it catalyzes the conversion of hypoxanthine to inosine
monophosphate and guanine to guanosine monophosphate, and plays a central role in purine
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Figure 4.6: Meta-analysis of ARIC EA, ARIC AA, and HCHS/SOL trait-observed
metabolite associations by phenotype. Dashed red line indicates Bonferroni-corrected
significance threshold at p ă 2.92ˆ 10´5.
metabolism and in the generation of purine nucleotide bases (guanine and adenine) through
the purine salvage pathway (GeneCards, 2021a).
4.4.2 Metabolite GWAS
We performed metabolite GWAS (mGWAS) on each ARIC metabolite, separately for
each ancestry group, using the GWAS sample of the cohort (see Methods section 4.6.3) (EA
N = 512, AA N = 596). For the EA group, the minimum number of genome-wide nominally
significant (p ă 10´4) variants among all metabolites was 542, the maximum number of vari-
ants was 16,530, and the median was 1,708 (Figure 4.7A). For the AA group, the minimum,
maximum, and median were 1,371; 41,070; and 3,379 respectively (Figure 4.7B).
A trans-ethnic meta-analysis of ARIC mGWAS, combining EA and AA GWAS results,
yielded a minimum of 190 genome-wide nominally significant (p ă 10´4) variants among all
metabolites, a maximum of 2,384 variants, and a median of 431 variants (Figure 4.8).
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Figure 4.7: ARIC distribution of the number of nominally significant (p ă 10´4) GWAS
variants (SNPs) per metabolite used for model training, by ancestry. (A) displays EAs, (B)
displays AAs.
Figure 4.8: ARIC meta-analysis distribution of the number of nominally significant
(p ă 10´4) GWAS variants (SNPs) per metabolite used for model training.
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Figure 4.9: Distribution of EA elastic net model training R2 (A), and model R2 versus
heritability (B). In (B), heritability (h2) estimates are black with 95% confidence intervals in
gray; elastic net model R2 values are red.
4.4.3 Model Training to Predict Metabolites Using Genetics
With the nominally significant variants from mGWAS (section 4.4.2), we performed
elastic net model training to select a parsimonious model of predictive variants (i.e. weights)
for each metabolite. We performed this model selection step separately for each racial group,
using the training sample of the cohort (EA N = 511, AA N = 604) (see Methods sections
4.6.3 and 4.6.5). Among the 245 metabolites included in model training, there were 123
metabolites for which we obtained an elastic net model for EAs and 115 metabolites with
an elastic net model for the AA group. The mean and median model R2 performance for EA
metabolites from model training was 0.0846 and 0.0638, respectively (Figure 4.9A). Mean
and median model R2 performance for AA metabolites was 0.0717 and 0.0513, respectively
(Figure 4.10A).
Figure 4.11 presents a comparison of the elastic net model R2 values from the ARIC
EA sample compared to those from the ARIC AA sample. We see some inconsistencies in
model performance between ancestry groups; however, some of the most well-performing
models (proline, Nacetyl1methylhistidine, aminooctanoate, trehalose, serotonin) do show
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Figure 4.10: Distribution of AA elastic net model training R2 (A), and model R2 versus
heritability (B). In (B), heritability (h2) estimates are black with 95% confidence intervals in
gray; elastic net model R2 values are red.
Figure 4.11: Comparison of ARIC EA versus AA elastic net model training R2. Metabolites
are limited to those with 2 or more non-zero coefficients from elastic net model training in
either the EA or AA ancestry groups.
some agreement. For example, proline has a relatively high elastic net model R2 in both an-
cestry groups, and we also find that the models for both ancestry groups include strong signal
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variants on chromosome 22 near strong known GWAS signals mapped to PRODH (Proline
Dehydrogenase 1). For example, rs2238732 (chr22:18927834; GRCh38.p13) has a strong
known GWAS association with proline measurements (Imaizumi et al., 2019) and other blood
metabolite measurements (Draisma et al., 2015). Moreover, rs2277834 (chr22:18923032;
GRCh38.p13) has recently been associated with proline measurements as well (Chai et al.,
2019). Furthermore, PRODH is known to encode a mitochondrial protein that catalyzes the
first step in proline degradation (GeneCards, 2021b) and is also known to be associated with
the disease Hyperprolinemia, Type I (OMIM, 2021). This provides meaningful context and
evidence for the consistent model R2 that we see for proline, in particular, across ancestry
groups.
We estimated the heritability of metabolites attributable to genome-wide SNPs and calcu-
lated variances using restricted maximum likelihood as implemented in GCTA (Yang et al.,
2011), separately for EAs and AAs (see Methods section 4.6.8). Although heritability esti-
mates constitute the upper limits of our model performance (R2), we did not limit our anal-
ysis to “heritable” metabolites. Heritability estimates are challenging in small sample sizes,
and we found that heritability estimates using all genotyped SNPs were, indeed, too noisy to
make meaningful inferences (Figure 4.9B and 4.10B). In particular, confidence intervals for
heritability estimates in both EA and AA groups were very wide, and we report little consis-
tency (Pearson r “ 0.0675) when comparing EA heritability to AA heritability (Figure 4.12).
Additionally, to determine whether any visible upward trend was present in the heritability-
sorted elastic net model R2 results, we limited the EA and AA metabolites to the list of those
on which we obtained an elastic net model with two or more non-zero coefficients and ap-
plied a lowess curve to the elastic net model R2 results (Figure 4.13). Unfortunately, we see
no upward trend in heritability-sorted elastic net model R2 results, and in fact, elastic net re-
sults tend to dip slightly downward when heritability estimates are at their highest point on
the right hand side of each figure.
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Figure 4.12: Comparison of ARIC EA versus AA heritability estimates (h2). Estimates for
all 245 metabolites are included.
Figure 4.13: ARIC EA (A) and ARIC AA (B) heritability (h2) estimates for metabolites with
an elastic net model containing two or more non-zero coefficients. Heritability (h2) estimates
are black with 95% confidence intervals in gray; elastic net model R2 values are red, with
lowess fitted line also in red.
Model training in the trans-ethnic meta-analysis did not benefit from increased sample
size or result in improved performance. Among the 245 metabolites, we obtained a predic-
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Figure 4.14: Distribution of meta-analysis elastic net model training R2.
tive model for 130. The mean model R2 performance was 0.051 and median model R2 was
0.042 (Figure 4.14), both values slightly lower than race-specific model R2 (Figures 4.9A
and 4.10A). Additionally, we found inconsistencies when comparing meta-analysis model
training results to race-specific model training results (Figure 4.15). Model training results
from race-specific analyses tend to be better than those from meta-analysis.
4.4.4 Metabolite Prediction in Testing Samples
With the model weights obtained from the elastic net training step in section 4.4.3, we
predicted metabolite measures in the testing sample of the cohort (EA N = 514; AA N = 648),
separately for each ancestry group (see Methods sections 4.6.3 and 4.6.6). Prediction R2 val-
ues, assessing the relationship between observed metabolite measures and predicted metabo-
lite measures are presented in Figures 4.16, 4.17, and 4.18 for EA metabolite prediction, AA
metabolite prediction, and a comparison of EA versus AA metabolite prediction R2, respec-
tively. In general, the genetically regulated component of metabolites was poorly predicted
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Figure 4.15: Distribution of meta-analysis elastic net model training R2 compared to EA
model R2 (A) and AA model R2 (B). Colors are based on model R2 performance. Green
indicates R2 ą 0.05 in both meta-analysis and race-specific analysis; purple indicates
R2 ą 0.05 in race-specific analysis only; blue indicates R2 ą 0.05 in meta-analysis only, and
red indicates R2 ď 0.05 in both meta-analysis and race-specific analysis.
Figure 4.16: Distribution of EA metabolite prediction R2.
for both ancestry groups. The mean and median model prediction R2 for EA metabolites was
0.02 and 0.0036, respectively (Figure 4.16). Mean and median model prediction R2 for AA
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Figure 4.17: Distribution of AA metabolite prediction R2.
metabolites was 0.0087 and 0.0012, respectively (Figure 4.17). Comparisons between EA
model prediction R2 and AA model prediction R2 are also inconsistent (Figure 4.18). How-
ever, EA model prediction tended to outperform AA model prediction, and we found that
some of the well-modeled metabolites also have relatively reasonable and consistent predic-
tion R2 (e.g. Nacetyl1methylhistidine, aminooctanoate, and trehalose) when comparing EAs
to AAs.
Not surprisingly, model prediction R2 in the meta-analyzed sample was also poor (predic-
tion R2 mean = 0.0056 and median = 0.0014; Figure 4.19), and meta-analysis did not provide
any improvement over race-specific analyses (Figure 4.20).
4.4.5 Phenotype Regressed on Predicted Metabolites
In the sample of ARIC participants who do not have observed metabolite measures, we
predicted metabolites using the model weights obtained from the elastic net training step
in section 4.4.3. We predicted metabolites in approximately 7,000 EA individuals and 900
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Figure 4.18: Comparison of ARIC EA versus AA prediction R2. Colors are based on
prediction R2 performance. Green indicates R2 ą 0.05 in both EA and AA; purple indicates
R2 ą 0.05 in EA only; blue indicates R2 ą 0.05 in AA only, and red indicates R2 ď 0.05 in
both EA and AA.
AA individuals (exact sample sizes by phenotype in Table 4.7) using only metabolites with
elastic net model R2 ą 0.05 (i.e. EA metabolites = 79, AA metabolites = 60). We regressed
hematological phenotypes on those predicted metabolites, separately for each ancestry group.
As expected, given our poor model prediction results in section 4.4.4, predicted metabo-
lites did not result in any statistically significant associations with hematological measures,
using a Bonferroni-corrected p-value threshold for EA at p ă 9.04 ˆ 10´5 and for AA at
p ă 1.19 ˆ 10´4. Some associations met a nominal level of significance (p ă 0.05) using
predicted metabolites, including 46 associations for EAs and 26 associations for AAs (Table
4.7 and Figure 4.21). Ten of the nominally significant associations based on predicted metabo-
lites with elastic model R2 ą 0.05 are identified as statistically significant associations using
observed ARIC metabolites as well (Appendix Table B.1). However, none of these associa-
tions have the same estimated direction of effect, and the estimates themselves differ wildly
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Figure 4.19: Distribution of meta-analysis metabolite prediction R2.
Figure 4.20: Distribution of meta-analysis metabolite prediction R2 compared to EA
prediction R2 (A) and AA prediction R2 (B). Colors are based on prediction R2 performance.
Green indicates R2 ą 0.05 in both meta-analysis and race-specific analysis; purple indicates
R2 ą 0.05 in race-specific analysis only; blue indicates R2 ą 0.05 in meta-analysis only, and
red indicates R2 ď 0.05 in both meta-analysis and race-specific analysis.
when comparing observed estimates to predicted estimates. Not surprisingly, the standard
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Table 4.7: ARIC trait-predicted metabolite associations by ancestry, significance level and
phenotype.
European African
N non-significant p ă 0.05 N non-significant p ă 0.05
Hematocrit 7,264 70 9 946 59 1
Hemoglobin 7,263 67 12 946 60 0
Lymphocyte 5,283 76 3 943 56 4
Monocyte 5,224 74 5 937 56 4
Neutrophil 5,257 74 5 943 55 5
Platelet 7,243 70 9 946 56 4
White blood count 7,264 76 3 946 52 8
Total 507 46 394 26
Figure 4.21: Distribution of ARIC trait-predicted metabolite -log10 p-values, by phenotype
for EAs (A) and AAs (B). Dashed vertical red line denotes nominal p-value threshold at
p ă 0.05.
error estimates for the predicted metabolites also tend to be much larger relative to those for
observed metabolites.
Similar to race-specific predicted metabolites, those metabolites predicted from trans-
ethnic meta-analysis did not result in any statistically significant associations with hemato-
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Table 4.8: ARIC trait-predicted metabolite associations from meta-analysis by significance
level and phenotype.
N non-significant p ă 0.05
Hematocrit 8,210 51 4
Hemoglobin 8,209 51 4
Lymphocyte 6,226 49 6
Monocyte 6,161 52 3
Neutrophil 6,200 48 7
Platelet 8,189 48 7
White blood count 8,210 46 9
Total 345 40
Figure 4.22: Distribution of ARIC meta-analysis trait-predicted metabolite -log10 p-values,
by phenotype. Dashed vertical red line denotes nominal p-value threshold at p ă 0.05.
logical measures, using a Bonferroni-corrected p-value threshold of p ă 5.67 ˆ 10´5. Forty
trait-metabolite associations met a nominal level of significance (p ă 0.05) using meta-
analysis predicted metabolites (Table 4.8 and Figure 4.22). Four of the nominally significant
associations based on meta-analysis predicted metabolites with elastic model R2 ą 0.05
are also identified as statistically significant associations with the same direction of effect
compared to race-specific observed ARIC metabolites (Table 4.9). Still, given the poor model
predictive performance, the evidence to support these observed trait-metabolite associations
as replicating in predicted metabolites is not entirely convincing.
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Table 4.9: ARIC association summary statistics using observed metabolites or meta-analysis predicted metabolites. Associations are
limited to those that are statistically significant with EA or AA observed metabolites, are nominally significant with meta-analysis
predicted metabolites, have an elastic net model R2 ą 0.05, and have the same direction of effect when comparing observed estimates
to predicted estimates.
Observed Meta-analysis Predicted
ancestry phenotype metabolite Estimate SE p-value Estimate SE p-value
AA hematocrit dihomolinolenate 0.14 0.024 8.00E-09 0.36 0.140 1.06E-02
EA hematocrit dihomolinolenate 0.14 0.027 3.60E-07 0.36 0.140 1.06E-02
AA hemoglobin dihomolinolenate 0.16 0.024 1.36E-11 0.34 0.140 1.52E-02
EA hemoglobin dihomolinolenate 0.14 0.026 8.27E-08 0.34 0.140 1.52E-02
AA neutrophil gammaglutamylalanine -0.13 0.023 1.55E-08 -0.33 0.112 3.01E-03
EA neutrophil gammaglutamylalanine -0.20 0.034 3.13E-09 -0.33 0.112 3.01E-03
AA WBC gammaglutamylalanine -0.14 0.023 1.59E-09 -0.23 0.100 2.13E-02
EA WBC gammaglutamylalanine -0.22 0.030 4.10E-13 -0.23 0.100 2.13E-0293
4.5 Discussion
In this chapter, we adapt the conceptually similar TWAS approach to create a novel
metabolome-wide association study approach (MWAS) that uses genetic variants to infer
heritable metabolite levels, instead of an mRNA transcript. We use the high throughput
metabolomics data (i.e. untargeted metabolomics analysis performed on serum samples from
ARIC Visit 1) in European Americans (EAs, N = 1,553) and African Americans (AAs, N
= 2,479) on 245 named metabolites from the Atherosclerosis Risk in Communities Study
(ARIC, The ARIC Investigators (1989)). We use these data to construct a MWAS reference
panel and then apply the MWAS approach to the study of hematological traits in EA and AA
populations.
In general, we report consistent associations with hematological measures among ARIC
EA, ARIC AA, and HCHS/SOL populations using observed metabolites, and we identified
hundreds of observed trait-metabolite associations upon trans-ethnic meta-analysis. However,
elastic net model performance in our training sample and especially prediction performance
in our testing sample were poor using our method on race-specific ancestry groups in ARIC.
Moreover, we found inconsistencies in elastic net model performance, metabolite prediction,
and heritability estimates when comparing ARIC EA results to those with ARIC AA results.
Unfortunately, without seeing some cross-ethnic consistency, it becomes challenging to make
meaningful inferences. In addition, we found that meta-analyzing the ARIC ancestry-specific
metabolite GWAS results, which provided a larger sample size for initially selecting a nom-
inal set of GWAS variants across the genome, did not improve model training or prediction
performance in subsequent analyses. Thus, not surprisingly, we were also not able to con-
fidently demonstrate that any of the trait associations with predicted metabolites replicated
those trait associations from observed metabolites. As a result, thus far, we are not yet able to
show substantive evidence that MWAS (using this particular method) is effective at predicting
metabolites.
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Nevertheless, we plan to explore additional methods that may improve various aspects
of our analytical pipeline. First, we plan to further explore the conclusions that can be drawn
from the large number of statistically significant observed trait-metabolite associations that
we identified in ARIC EA, ARIC AA, and HCHS/SOL combined meta-analysis. While we
highlighted platelet counts associated with hypoxanthine and guanosine, there are likely
to be several biologically impactful relationships among the many statistically significant
associations that we have identified. Additionally, we find it imperative to investigate other,
more recent, methods including BGW-TWAS (Luningham et al., 2020) and TIGAR (Nagpal
et al., 2019) to determine if these approaches allow for better metabolite prediction in this
scenario in which there is no effective way of designating cis versus trans variants for model
training. Moreover, in a recent paper exploring the effects of Alzheimer’s disease risk loci
on brain protein abundance, Wingo et al. (2021) adapt the TWAS/FUSION (Gusev et al.,
2016) approach to perform a proteome-wide association study of Alzheimer’s disease in
which they implicate new proteins in Alzheimer’s disease pathogenesis. This adaptation
of TWAS/FUSION to proteins highlights the utility and effectiveness of adapting TWAS
methods to other ’omics measures. Thus, an adaptation of TWAS/FUSION to metabolites
may aid in improving model performance and metabolite prediction in our analysis as well.
A clear limitation in this analysis is due to the small sample size of ARIC and HCHS/-
SOL. While we were still able to identify observed metabolite associations with hematologi-
cal traits, we were unable to obtain consistent results between ARIC EA and AA groups for
each procedure in the pipeline – model training, metabolite prediction, heritability estimates.
This type of method may simply require a larger sample size, particularly for model training.
As mentioned, we were unable to calculate precise and meaningful heritability estimates. Us-
ing a larger sample size, we may also be more successful at calculating heritability estimates;
in turn, we may be able to select a heritability threshold for metabolites which could screen
for metabolite heritability before attempting to predict metabolite abundance.
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Additionally, in our analysis, we only have access to cross-sectional data, measured at
a single time point for both ARIC and HCHS/SOL. Metabolite abundance is considered
to be very dynamic, as many metabolic reactions take place continuously within cells, and
metabolite genetics associations may vary by both time and context (Gallois et al., 2019).
In summary, we have yet to show that predicting metabolite abundance via MWAS
allows better interpretation of existing genetic data, nor have we shown that it can iden-
tify metabolic pathways which mediate the heritable component of complex traits, includ-
ing hematological measures. However, we continue to focus this research on developing a
method to impute metabolites from genetic data, which could theoretically be applied to any
complex trait. Using a larger sample size containing measured metabolites for model training,
such as the UK Biobank NMR-based data in 120,000 individuals, will provide further insight
into whether this method has the potential to perform well. This would allow us to perform
MWAS in those individuals who do not have measured metabolites but only have genotype




4.6.1.1 Atherosclerosis Risk in Communities Study
We use the high throughput metabolomics data in European Americans (EAs, N = 1,553)
and African Americans (AAs, N = 2,479) from the Atherosclerosis Risk in Communities
Study (ARIC, The ARIC Investigators (1989)) to construct a MWAS reference panel and then
apply the MWAS approach to the study of hematological traits in EA and AA populations.
In ARIC, metabolites were measured from fasting serum samples (N = 4,032) collected
at the baseline ARIC examination (1987-1989) and stored at -80 degrees Celsius until anal-
ysis by Metabolon, Inc. (Durham, NC) in 2010 and 2014. Serum samples were prepared
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using Metabolon’s standard solvent extraction method, where extracted samples were split
into equal parts for analysis on the 1) untargeted, gas chromatography-mass spectrometry
and 2) liquid chromatography-mass spectrometry (GC-MS and LC-MS)-based metabolomic
quantification platforms. Instrument variability was determined by calculating the median
relative standard deviation (SD) for the internal standards that are added to each sample prior
to injection into the mass spectrometers. Overall process variability was determined by calcu-
lating the median relative SD for all endogenous metabolites (i.e. non-instrument standards)
present in 100% of the technical replicate samples. In ARIC, 384 metabolites were detected
and semi-quantified on both batches, and 285 out of 384 had missing rate ď 25%. A set of
97 duplicate samples was used in both batches, and Pearson correlation coefficients (r2) were
calculated between the 97 pairs for these 285 metabolites. The r2 ranged from -0.09 to 0.99,
with mean = 0.63 and median = 0.71. Forty metabolites with r2 ă 0.3 were excluded, leaving
245 metabolites for this study. Metabolites were then mean centered and scaled by standard
deviation prior to analysis.
We analyze a set of 7 phenotypes including red blood cells (hematocrit and hemoglobin),
white blood cells (lymphocyte count, monocyte count, neutrophil count, white blood cell
count), and platelets measured at ARIC Visit 1. All phenotypes were adjusted for age, age
squared, sex, study site, and top 10 principal components and were inverse normalized prior
to analysis.
4.6.1.2 Hispanic Community Health Study/Study of Latinos
A comprehensive description of the community-based cohort study HCHS/SOL has pre-
viously been published (LaVange et al., 2010). Participants 18-74 years of age at their base-
line examination were recruited through a stratified multistage area probability sample design
from four communities (San Diego, California; Chicago, Illinois; The Bronx, New York, New
York; and Miami, Florida). Overall, 16,415 participants, representing major self-reported
US Hispanic/Latino background groups (Mexicans, Puerto Ricans, Cubans, Central Ameri-
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cans, Dominicans, and South Americans), took part in baseline examinations that occurred
in June 2008-July 2011. Second visits were performed in 2014-2017, and the completion of
third visits began in 2020 and is ongoing. A random subset of 3,926 participants with avail-
able genetic and metabolomic measures from their first visit were included in the present
analysis. The HCHS/SOL study was approved by institutional review boards at participating
institutions. Written informed consent was obtained from all participants.
We analyze a set of 7 phenotypes including red blood cells (hematocrit and hemoglobin),
white blood cells (lymphocyte count, monocyte count, neutrophil count, white blood cell
count), and platelets. Blood cell phenotypes were inverse normalized prior to analysis. Asso-
ciation analysis of hematological traits with metabolites used models adjusted for age, sex,
center, and regional subgroup. Sampling weights were included as fixed effects and family ID
was included as a random effect. Specifically, we used linear mixed effect models in R with a
maximum likelihood option to account for families in HCHS/SOL (nlme package).
In HCHS/SOL, fasting blood samples were collected, processed, and stored at -70 de-
grees Celsius since collection. Stored serum samples at the HCHS/SOL baseline examination
were used for metabolomic profiling. The metabolomic profiling was conducted at Metabolon
(Durham, NC) with Discovery HD4 platform in 2017. Serum metabolites were quantified
with untargeted, liquid chromatography-mass spectrometry (LC-MS)-based quantifica-
tion protocol (Evans et al., 2009; Ohta et al., 2009). The platform captured a total of 1,136
metabolites, including 782 known and 354 unknown metabolites. For quality control and bet-
ter understanding of the biological mechanisms underlying disease etiology, only metabolites
with missing rates ă 50% were considered in this study, including 687 named metabolites.
Values below the detection limit were set to the minimum value, and then metabolites were
centered at the mean and scaled by their standard deviation. We focus on metabolites that are
both named and heritable.
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4.6.2 Trait-Metabolite Association Analysis
We performed a simple linear regression analysis of each hematological phenotype re-
gressed on each metabolite in ARIC to examine their relationships among the EA group and
the AA group separately. To determine statistical significance of these results and account
for multiple testing, we used a Bonferroni correction with 245 metabolites X 7 phenotypes
= 1,715 association tests, implying p ă 0.05{1715 “ 2.92 ˆ 10´5. This same approach was
used for trait-metabolite association analysis in HCHS/SOL, while accounting for the study’s
complex survey sampling design (see Methods section 4.6.1.2).
We used METAL (Willer et al., 2010) to perform p-valued-weighted trans-ethnic meta-
analyses of observed metabolite-trait associations. First, we combined ARIC EA and ARIC
AA observed metabolite-trait associations in a meta-analysis to obtain ARIC-specific associ-
ation statistics (i.e. Z-scores and p-values). Then we combined ARIC meta-analysis results
with HCHS/SOL observed metabolite-trait associations to obtain the final meta-analyzed
sample. In comparisons of direction of effect, we compare the direction of the ARIC meta-
analyzed Z-score to the direction of the HCHS/SOL estimated effect of observed metabolite
on hematological trait.
4.6.3 Random Selection of Participants
We randomly divided the EA sample and the AA sample by three, using SAS 9.3 PROC
PLAN. We used one-third of the samples to select nominally significant variants associated
with metabolites (see Section 4.6.4 for details on significance criteria); we refer to this third
of the sample as the “GWAS sample”. We used another one-third of the samples to train elas-
tic net models using the nominally significant variants identified in metabolite GWAS, testing
methods and deriving variant weights for MWAS in ARIC EAs and AAs separately (see Sec-
tion 4.4.3 for model training details); we refer to this third of the sample as the “testing sam-
ple”. In the remaining one-third of the samples, we assessed the performance of ARIC EA
and AA derived weights by computing Pearson R2 between observed and imputed metabolite
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measures (see Section 4.6.5 for performance assessment details); we refer to this third of the
sample as the “testing sample”.
4.6.4 Metabolite GWAS
The entire ARIC sample on which we have genotype data (EA N = 9,345; AA N = ,2874)
was imputed to TOPMed freeze 8 (NHLBI Trans-Omics for Precision Medicine, 2020) using
the Michigan Imputation Server (https://imputationserver.sph.umich.edu/index.html#!) and
was filtered for imputation quality to only include variants with R2 ą 0.3. We used EPACTS
version 3.3.0 (Kang, 2019) to generate a genetic relationship matrix, separately, for each
racial group, and specified a minimum minor allele frequency of 0.01. We performed GWAS
for each metabolite, separately, using the GWAS sample for each racial group (EA N = 512,
AA N = 596), specifying q.emmax as the test statistic. Nominal significance was based on a
p-value threshold of 1ˆ 10´4.
We used METAL (Willer et al., 2010) to perform a p-valued-weighted trans-ethnic meta-
analysis of metabolite GWAS associations, combining results from ARIC EAs and ARIC
AAs.
4.6.5 Model Training to Predict Metabolites Using Genetics
Genotype dosages for all genome-wide, nominally significant variants from each metabo-
lite GWAS (mGWAS) (Section 4.6.4) were included in an elastic net model using the training
sample, separately for each racial group (EA N = 511, AA N = 604). Only nominally signif-
icant variants with R2 ą 0.3, MAF ą 0.01, and allele counts ě 10 from the GWAS sample
were considered for model training. Elastic net model training was performed in R using
cross-validation for glmnet (cv.glmnet; https://www.rdocumentation.org/
packages/glmnet/versions/4.1/topics/glmnet) with elastic net mixing pa-
rameter alpha = 0.5 and 10-fold cross-validation.
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We used elastic net model R2 to determine model performance of the selected variants
on each metabolite. A metabolite with a model R2 ă 0.05 was deemed as having poor model
performance and was not further evaluated in subsequent analyses.
4.6.6 Metabolite Prediction in Testing Samples
We further assessed the predictive performance of ARIC EA and AA derived weights
from the model training step by first multiplying those weights by genotype dosage (via
matrix multiplication) to predict metabolite measures in the testing sample of the cohort (EA
N = 514; AA N = 648). We then computed the squared Pearson correlation between observed
metabolite measurements and predicted metabolite measurements.
In this same manner, we additionally predicted metabolite measures for the EA and AA
individuals who did not have observed metabolite measures, but for whom we have genotype
data (EA « 7, 000; AA « 900; exact sample sizes by phenotype are available in Table 4.7).
The predicted metabolite measures in this sample of the cohort are associated with hematolog-
ical phenotypes in Section 4.6.7.
4.6.7 Phenotype Regressed on Predicted Metabolites
Similar to Section 4.6.2, we performed a simple linear regression analysis (using SAS
9.3) of each hematological phenotype regressed on each predicted metabolite to examine their
relationships among the EA group and the AA group separately. We limited this analysis to
those metabolites with elastic net model R2 ą 0.05 (79 metabolites for EAs and 60 metabo-
lites for AAs). To determine statistical significance of these results and account for multiple
testing, we used a Bonferroni correction of p ă p0.05{p79 ˆ 7qq “ 9.04 ˆ 10´5 for EAs and
p ă p0.05{p60ˆ 7qq “ 1.19ˆ 10´4 for AAs. We defined a nominal significance threshold at
p ă 0.05 for both ancestry groups.
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4.6.8 Metabolite Heritability
The heritability of metabolite abundance defines an upper bound to how well we can pre-
dict a trait. We estimated the narrow-sense heritability for each metabolite using a variance-
component model with a genetic relationship matrix (GRM) estimated from genotype data
(separately for European Americans and African Americans), as implemented in GCTA
(Yang et al., 2011).
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CHAPTER 5: CONCLUSION
In this dissertation, I focus on transcriptome-wide association studies (TWAS) as a gene-
based method to systematically interrogate the genome and provide insight into the biological
mechanisms underlying associations between variants and a wealth of complex traits iden-
tified by GWAS. TWAS achieves this by leveraging the regulatory influence of variants on
gene expression in order to infer the effect of genetically-regulated gene expression on a
complex trait. In Chapter 1, I detail many of the methodological differences in TWAS mod-
eling assumptions and the constraints that they place on the estimation of SNP-gene effect
sizes. Additionally, I discuss the importance of considering a single tissue versus multiple
tissue gene expression reference panel, highlight TWAS methods that utilize individual and/or
summary level data, and examine recent methodological developments in the use of distal
variants in model training. I further call attention to many of the challenges inherent in TWAS
fine-mapping and the interpretation of TWAS results. I encourage researchers to take these
challenges into consideration and identify appropriate solutions in order to avoid drawing
hasty or over-simplistic conclusions from TWAS results.
In Chapter 2, I analyze hematological measures as highly heritable and important inter-
mediate clinical phenotypes for many acute and chronic diseases. Although recent genome-
wide association studies (GWAS) have identified thousands of loci containing hematological-
associated variants, the causal genes underlying these associations are often uncertain. To
better understand the underlying genetic regulatory mechanisms, I performed a TWAS using
PrediXcan to systematically investigate the association between genetically-predicted gene
expression and hematological measures in 54,542 individuals of European ancestry from the
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Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort. I found 239
significant gene-trait associations with hematological measures. Among this set of 239 asso-
ciations, I replicated 71 at p ă 0.05 with same direction of effect for the blood cell trait in
a meta-analysis of TWAS results consisting of up to 35,900 European ancestry individuals
from the Women’s Health Initiative (WHI), the Atherosclerosis Risk in Communities Study
(ARIC), and BioMe Biobank. I further attempted to refine this list of candidate genes by per-
forming conditional analyses, adjusting for individual variants previously associated with
these hematological measures, and performed further fine-mapping of TWAS loci.
However, interpreting TWAS results poses many challenges, particularly in large-scale
analyses with hundreds of statistically significant signals across the genome (e.g. GERA
TWAS in Chapter 2). Differentiating between causal and spurious signals and including rele-
vant results from other genetic studies and gene expression reference panels are key compo-
nents in results-interpretation. To assist with the interpretation of TWAS findings, I designed
an R Shiny application (Chapter 3) and R package (Appendix A) called LocusXcanR to
interactively visualize TWAS results, one genomic locus at a time, by integrating our TWAS
results with additional genetic data sources (e.g. GWAS, TWAS from other gene expression
reference panels, conditional analyses, known GWAS variants, etc.). Although TWAS signals
are often assumed to highlight the causal gene at a locus, LocusXcanR emphasizes the chal-
lenges in accepting TWAS signals as causal, especially at complex loci containing multiple
significant genes, or where genes are poorly predicted by a reference panel. My results and R
Shiny application not only highlight frequently overlooked challenges with TWAS but also
illustrate the complexity of TWAS fine-mapping efforts. Moreover, LocusXcanR aids in
TWAS results interpretation and can be extended to include other ’omics data in a broadly
approachable, interactive, and visual format.
In Chapter 4, I apply the TWAS framework to the study of metabolites. Because the mea-
sured concentrations of these small molecules reflect the underlying biochemical activity and
state of cells and tissues, they may offer additional biological insights into associations iden-
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tified by GWAS. However, analyzing metabolites via a TWAS-like framework poses an ad-
ditional challenge because it is not possible to distinguish between cis- and trans-variants in
the model training process. I explore a manual method for selecting a nominal set of genome-
wide variants to use for model training in European and African American individuals in
ARIC. I achieve this by dividing the ARIC sample into three – one-third of the sample used
for selecting a nominally-significant set of genome-wide variants (i.e. GWAS sample), one-
third of the sample used for elastic net model training (i.e. training sample), and one-third of
the sample used for predicting metabolite levels from trained models (i.e. testing sample). In
analyzing ARIC European and African American individuals separately, I found agreement in
association statistics between EA and AA groups when using observed metabolite measures.
Furthermore, I identified agreement between ARIC and HCHS/SOL association statistics
with observed metabolites as well. This provides evidence that strong and reproducible cor-
relations between hematological traits and metabolite abundance exist. However, elastic net
model training and model prediction steps using the current analytical pipeline did not yield
performance measures suitable enough for us to make meaningful inferences at this time.
Nonetheless, this is a question that warrants further exploration of various analytical methods
(e.g. BGW-TWAS, TIGAR, TWAS/FUSION) for deriving SNP-based weights. While we
have not yet identified any substantive evidence in support of the MWAS framework, we have
also not yet deemed this approach to be entirely ineffective.
Overall, I have provided evidence that TWAS results enrich our understanding of GWAS,
can help to explain trait variation, and are superior to merely selecting the nearest gene.
While I show that TWAS may help in some cases to pinpoint likely causal genes, I emphasize
the need for investigators to carefully interpret TWAS results in context. As I continue to
work to expand the TWAS framework to other ’omics data, it is vitally important to consider
these challenges alongside other obstacles (such as small sample sizes and trans-ethnic cohort
differences) related to model training and prediction, as evidenced by MWAS in Chapter 4.
Exploring genome-wide approaches to selecting variants for model training and improving
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upon current fine-mapping methods will further enhance and refine results. Furthermore,
future studies involving minority cohorts and/or ad-mixed populations will provide essen-
tial diversification to our overall understanding of biological processes. Finally, results from
the application of the TWAS framework to predict transcripts, proteins, and metabolites can
assist researchers in formulating mechanistic hypotheses for functional experimental vali-
dation that would not have otherwise been possible. Incorporating subject matter expertise
together with a clearer understanding of the relationship between TWAS, GWAS, MWAS,
and even proteome-wide association study results (in future studies), this rich set of predicted
multi-omics measures provides more comprehensive knowledge of the underlying functional
mechanisms responsible for observed phenotypes. In turn, these analyses can improve our
understanding and treatment of a broad range of acute and chronic diseases, which has the
potential to have a profound public health impact.
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APPENDIX A: ADDITIONAL DETAILS FOR CHAPTER 3
This appendix contains the detailed documentation (vignette) for the LocusXcanR
R package. LocusXcanR is currently available on GitHub at https://github.com/
amanda-tapia/LocusXcanR.
A.1 R Package Information
title: LocusXcanR: An R Shiny App to Visualize TWAS Results Integrated with Other
’Omics Studies
date: Created: June 8, 2020; Updated: March 1, 2021
author: Amanda L. Tapia
package: LocusXcanR
A.2 Abstract
Transcriptome-wide association studies (TWAS) relate predicted gene expression to
traits of interest and can help us understand biological mechanisms underlying associations
identified in other genetic studies. Yet, interpreting TWAS results can be challenging, par-
ticularly in large-scale analyses with hundreds of statistically significant signals across the
genome. Differentiating between causal and spurious signals and including relevant results
from other genetic studies and gene expression reference panels are key components in
results-interpretation. LocusXcanR is an R package that creates an R Shiny application
to interactively visualize TWAS results by integrating them with detailed data from multiple
sources, one genomic locus at a time. Although TWAS signals are often assumed to highlight
the causal gene at a locus, the app emphasizes the challenges in accepting TWAS signals as
causal, especially at complex loci with multiple significant genes, or where genes are poorly
predicted by a reference panel. Thus, our app aids in TWAS results interpretation and can
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be extended to include other ’omics data in a broadly approachable, interactive, and visual
format.
A.3 Introduction
The interpretation of TWAS results is not always straightforward and can be quite chal-
lenging, especially for large-scale analyses, such as the Genetic Epidemiology on Adult
Health and Aging (GERA) cohort (N « 55, 000) and UK Biobank (N « 500, 000). Care
must be taken to interpret TWAS results in context (e.g. alongside information known from
other ’omics studies such as GWAS), understand how multiple TWAS signals at a given lo-
cus may be affected by correlated gene expression and/or the sharing of model variants, and
evaluate how fine-mapping results either clarify the most likely causal genes, or may be con-
founded by some of the same challenges as the original TWAS analysis.
Thus, in order to facilitate the interpretation of TWAS findings, we present an R package
which creates an R Shiny application designed to interactively visualize TWAS results. We
discuss, in detail, the features of the R package and R Shiny application and show how it can
be used to quickly interpret very complex TWAS loci in the context of prior knowledge from
GWAS.
A.4 LocusXcanR Function
The LocusXcanR function takes several datasets as input, including TWAS results,
GWAS results, gene expression reference panel weights, GWAS LD, and predicted expres-
sion correlation. These results are then integrated into a single HTML web page via R Shiny,
and the interactive visualizations and data tables can then be used to facilitate TWAS results
interpretation.
The LocusXcanR function contains the following required and optional parameters. A
description of each parameter is listed in the sections that follow.
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LocusXcanR(twas result, weight tbl, study name = “”, pred exp corr, condi-
tional present = FALSE, multiple tissues = FALSE, known variants, known gwas,
db genes, all gwas, ld gwas, ref expr name = “”, head details = “”, method details
= “”, primary tissue, meta present = FALSE, ideogram present = FALSE, genome build,
cytoband ds, add UI = “”, add server = “”)
A.4.1 Required Parameters
The LocusXcanR function contains the following required parameters and their defini-
tions:
• twas result: character, file path to TWAS results (required). See TWAS results
dataset section below for more details.
• pvalthresh: numeric, -log10 p-value threshold for TWAS results.
• weight tbl: character, file path to TWAS weights database (required). See Weights
table section below for more details.
• known variants: character, file path to known GWAS variants (required). See
Known variants dataset section below for more details.
• pred exp corr: character, file path to predicted expression correlation (required).
See Predicted expression correlation dataset section below for more details.
• known gwas: character, file path to study GWAS data matching known variants (re-
quired). See Known GWAS dataset section below for more details.
• db genes: character, file path to a list of genes in the database (required). See Refer-
ence panel genes section below for more details.
• all gwas: character, file path to study GWAS data (required). See GWAS results
dataset section below for more details.
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• ld gwas: character, file path to the LD among study variants or an LD reference panel
(required). See LD GWAS section below for more details.
A.4.2 Optional Parameters
The LocusXcanR function contains the following optional parameters and their defini-
tions:
• study name: character, the name of the study/cohort (optional, default is missing).
For example, study name = "Genetic Epidemiology on Adult Health
and Aging" or study name = "GERA".
• conditional present: logical, TRUE if conditional analysis results are available
for plotting, FALSE otherwise (default is FALSE). See TWAS results dataset section
below for more details on including conditional analysis results.
• multiple tissues: logical, TRUE if TWAS results are available from more than
one tissue, FALSE if TWAS results are only available from a single tissue or a multi-
tissue analysis (default is FALSE). This parameter can be used to compare, for example,
results from a primary tissue gene expression reference panel (e.g. Depression Genes
and Networks whole blood gene expression) to one or more secondary tissue gene ex-
pression reference panel(s) (e.g. Genotype-tissue Expression Project whole blood gene
expression), when multiple tissues = TRUE. See TWAS results dataset section
below for more details on including secondary tissue gene expression reference panels.
Note: This functionality is not currently available as of the date of this publication. The
application only displays results for a single-tissue TWAS analysis or a multi-tissue
analysis, but cannot be used to compare TWAS results from multiple tissues at this
time.
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• ref expr name: character, name of the reference expression data set used in the anal-
ysis (optional, default is missing). For example ref expr name = "Depression
Genes and Networks whole blood" or ref expr name = "DGN".
• head details: character, any additional header details to be included in the app (op-
tional, default is missing). HTML formatting commands may be used. See Frequently
Asked Questions section below for head details examples.
• method details: character, detailed methods section (optional, default is missing).
HTML formatting commands may be used. See Frequently Asked Questions section
below for method details examples.
• primary tissue: character, if multiple tissues are available for analysis, list the
name of the primary tissue (required if multiple tissues = TRUE). For exam-
ple, if you have results to compare from DGN and GTEx, and DGN is your primary
tissue reference panel, then primary tissue = "DGN". The character string
given to primary tissue must match a “tissue” name in the dataset loaded by
twas result. See TWAS results dataset section below for more details.
• meta present: logical, TRUE if results from TWAS meta-analysis are present for
comparison, FALSE otherwise (optional, default is FALSE).
• meta thresh: numeric, p-value threshold for meta-analysis results (required if
meta present = TRUE).
• ideogram present: logical, TRUE if an IdeogramTrack should be plotted, FALSE
otherwise (optional, default is FALSE).
• genome build: character, the genome build for the IdeogramTrack data (required
if ideogram present = TRUE). For example, genome build = "hg19" for
Genome Reference Consortium Human Build 37 (GRCh37).
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• cytoband ds: character, file path to the cytogenetic bands data set (required if
ideogram present = TRUE). See Ideogram plot section below for more details
on including an IdeogramTrack in the app.
• add UI: character, additional elements to add to UI (optional, default is missing). This
parameter can be used to include your own additional items at the end of the UI.
• add server: character, additional elements to add to server (optional, default is miss-
ing). This parameter can be used to include your own additional items in the server.
A.5 Data Pre-processing
A.5.1 TWAS Results Dataset (twas ds)
The TWAS results dataset includes, at the very minimum, TWAS results (in the form of a
p-value) from a primary TWAS analysis. P-values from a primary TWAS analysis may come
from a single-tissue TWAS analysis, a multi-tissue TWAS analysis, or a TWAS meta-analysis.
The TWAS results dataset may optionally include results from a TWAS meta-analysis (e.g.
for replication), TWAS conditional analysis, and/or TWAS results from secondary tissue gene
expression reference panels for comparison.
The dataset twas ds requires the following variables:
• tissue: character, name (or an abbreviated name) of the tissue reference panel
• locus: integer, value indicating the locus number
• locstart: integer, value indicating the genomic start position of the locus
• locstop: integer, value indicating the genomic stop position of the locus
• chr: integer, chromosome number
• index: character, the index (most significant) gene within the locus
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• pheno: character, the name of the phenotype being analyzed (may be one or more
phenotypes)
• genestart: integer, value indicating the genomic start position of the gene (may be
the gene start position or transcription start site or whatever starting position you would
like to plot for the gene)
• genestop: integer, value indicating the genomic stop position of the gene (may be
the gene stop position or transcription stop site or whatever stopping position you
would like to plot for the gene)
• p: numeric, p-value of the TWAS association test between phenotype and predicted
gene expression
• genename: character, the name of the gene (may be the gene name or the ENSMBL
ID or any other name you use to identify the gene)
• SignifGene: boolean, indicator of whether the gene-trait association is statistically
significant (1 if significant, 0 otherwise)
Optional variables may also be included in the twas ds dataset. These include the fol-
lowing:
• p meta: numeric, p-value from a TWAS meta-analysis used for replication, if avail-
able (required if meta present = TRUE)
• p conditional: numeric, p-value from a TWAS conditional analysis, if available
(required if conditional present = TRUE)
Additional variables (beyond those that are required or optional) may also be included in
the twas ds dataset. Any additional variables will be ignored when plotting figures but will
be printed in data tables within the application. Figure A.1 displays an example of twas ds.
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Figure A.1: Example of R shiny twas ds dataset.
A.5.2 GWAS Results Dataset (all gwas)
The GWAS results dataset all gwas contains all of the analytic cohort GWAS p-values
that you wish to plot. It is recommended that you subset the GWAS results dataset based
on a p-value threshold (e.g. only include variants with GWAS p-value ă 0.05). The dataset
contains variant information, the GWAS p-value, and the locus in which the variant needs to
be plotted.
The dataset all gwas requires the following variables:
• SNP: character, indicating chromosome : position : allele1 : allele2
• PVAL: numeric, the GWAS p-value for the variant in the analytic cohort
• LOCUS: numeric, the locus number in which you wish to plot the variant
Additional variables may also be included in the all gwas dataset (beyond those that
are required). Any additional variables will be ignored. An example of all gwas is dis-
played in Figure A.2.
A.5.3 Weights Table (weight tbl)
The weight tbl dataset contains a set of genes from the primary gene expression
reference panel along with their corresponding predictive model variant weights. This data
set is used to connect TWAS genes to their respective GWAS model variants and report the
weight and direction of the effect.
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Figure A.2: Example of R shiny all gwas dataset.
The dataset weight tbl requires the following variables:
• rsid: character, the RSID of the model variant
• gene: character, the name of the gene
• weight: numeric, the weight corresponding to the effect of the model variant on the
gene
• ref allele: character, the reference allele
• eff allele: character, the effect allele
• chr: numeric, chromosome number
• position: numeric, genomic position of the model variant
Additional variables may also be included in the weight tbl dataset (beyond those
that are required). Any additional variables will be ignored. An example of weight tbl is
displayed in Figure A.3.
A.5.4 Known Variants Dataset (known variants)
The known variants dataset contains a list of GWAS sentinel variants within the re-
gion. GWAS sentinel variants may come from GWAS Catalog or some other curated list (e.g.
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Figure A.3: Example of R shiny weight tbl dataset.
from the most recent and/or comprehensive GWAS for your trait of interest). This dataset is
used to identify TWAS genes which have already been assigned to GWAS variants and/or
identify within-cohort GWAS variants which have already been identified by previous GWAS
studies.
The dataset known variants requires the following variables:
• chr: numeric, the chromosome number for the sentinel variant
• position: numeric, the genomic position of the sentinel variant
• genename: character, the name of the gene that has been assigned by the sentinel
variant
• incohort: boolean, indicator identifying whether the sentinel variant is also well-
imputed in the analytic cohort (0 = sentinel variant is not in the analytic cohort, 1 =
sentinel variant is in the analytic cohort)
• effectallele: character, the effect allele of the sentinel variant
• otherallele: character, the alternate allele of the sentinel variant
Additional variables may also be included in the known variants dataset, beyond
those that are required. Any additional variables will be printed in the data table reported in
the application. Figure A.4 displays an example of known variants.
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Figure A.4: Example of R shiny known variants dataset.
A.5.5 Known GWAS Dataset (known gwas)
The known gwas dataset contains the set of variants that are included in both the ana-
lytic GWAS cohort and are known sentinel GWAS variants from other GWAS studies. The
dataset includes a variant identifier along with the GWAS p-value for the analytic cohort and
the locus number in which you wish to plot the variant.
The dataset known gwas requires the following variables:
• SNP: character, an identifier for the GWAS variant in the analytic cohort given by chr :
position : allele1 : allele2
• PVAL: numeric, the GWAS p-value for the variant in the analytic cohort
• Locus: numeric, the locus number in which you wish to plot the variant
Additional variables (beyond those that are required) may also be included in the dataset.
Any additional variables will be printed in the data table reported in the application. Figure
A.5 displays an example of known gwas.
A.5.6 Predicted Expression Correlation Dataset (pred exp corr)
The predicted expression correlation dataset is an M ˆM matrix of M genes required
for plotting, which contains pairwise correlations between each gene in the matrix. You may
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Figure A.5: Example of R shiny known gwas dataset.
Figure A.6: Example of R shiny pred exp corr dataset.
include all genes from your TWAS analysis; however, for computational efficiency, it is rec-
ommended that you only include those genes that you wish to plot (e.g. only the statistically
significant genes and those previously known from GWAS). This correlation matrix must be
in .Rdata format, and the name of the correlation matrix object must be saved as capital M.
Figure A.6 displays an example of pred exp corr.
A.5.7 GWAS LD (ld gwas)
The dataset containing pair-wise LD values among the predictive model variants at the
locus is specified by the ld gwas parameter. The dataset includes chromosome and genomic
position for each variant, and each row in the table additionally contains the LD between the
pair-wise variants and the locus in which the variants should be plotted. Chromosome and
genomic position in this table should match the chromosome and genomic position of the
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Figure A.7: Example of R shiny ld gwas dataset.
model variants in the weight tbl dataset. The variables chra and posa at each locus
represent the chromosome and position for the index SNP at the locus.
The dataset ld gwas requires the following variables:
• chra: numeric, the chromosome number for variant (a). This is for the index variant at
the locus.
• posa: numeric, the genomic position for variant (a). This is for the index variant at the
locus.
• chrb: numeric, the chromosome number for variant (b)
• posb: numeric, the genomic position for variant (b)
• corrab: numeric, LD between variant (a) and variant (b)
• locus: numeric, the locus in which these variants will be plotted
Additional variables (beyond those that are required) may also be included in the dataset.
Any additional variables will be ignored in the application. Figure A.7 displays an example of
ld gwas.
A.5.8 Reference Panel Genes (db genes)
The db genes dataset contains a list of genes from the primary gene expression refer-
ence panel that were either not predicted in the analytic cohort or no gene expression model
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Figure A.8: Example of R shiny db genes dataset.
was fit for the gene. This data set is used to determine whether there are any genes from the
reference panel which were not predicted in the analytic cohort or no gene expression model
was fit for the gene, but one or more GWAS sentinel variants implicate the gene as potentially
causal.
The dataset db genes requires the following variables:
• genename: character, the name of the gene
• genestatus: boolean, status indicator for the gene. 0 = gene was not predicted in the
analytic cohort, 1 = no gene expression model was fit for the gene
Additional variables (beyond those that are required) may also be included in the dataset.
Any additional variables will be ignored in the application. Figure A.8 displays an example of
db genes.
A.5.9 Ideogram Plot (cytoband ds)
A note on cytogenetic bands: Each human chromosome has a short arm (“p” for “petit”)
and long arm (“q” for “queue”), separated by a centromere. The ends of the chromosome are
called telomeres. Each chromosome arm is divided into regions, called cytogenetic bands,
that can be seen using a microscope and special stains. The cytogenetic bands are labeled p1,
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Figure A.9: Example of R shiny cytoband ds dataset.
Figure A.10: Example of R shiny Ideogram plot on chromosome 3 highlighting genomic
positions from 51744800 to 53804965.
p2, p3, q1, q2, q3, etc., counting from the centromere out toward the telomeres. At higher
resolutions, sub-bands can be seen within the bands. The sub-bands are also numbered from
the centromere out toward the telomere.
The dataset cytoband ds used to identify the cytogenetic bands in IdeogramTrack()
is typically downloaded directly from UCSC. For example, the example data used here was
obtained from the UCSC genome annotation database for the February 2009 assembly of
the human genome (hg19, GRCh37 Genome Reference Consortium Human Reference
37 (GCA 000001405.1)), downloaded from http://hgdownload.cse.ucsc.edu/
goldenpath/hg19/database/.
Figure A.9 displays an example of cytoband ds. Figure A.10 displays an example of
the output from IdeogramTrack() which uses the cytogenetic band dataset cytoband ds.
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Figure A.11: Example of LocusXanR’s LocusZoom mirror plot.
A.6 LocusXcanR Examples
Two key visualizations within the LocusXcanR application explore the interplay be-
tween gene co-regulation and variant linkage disequilibrium (LD) within each locus. The
LocusZoom-like mirror plot (Figure A.11), in the top panel, displays the correlation among
genes with the index gene, and in the bottom panel displays the LD among variants with the
index variant, while connecting genes to their predictive model variants and highlighting their
relative -log10 p-values.
A network visualization plot in LocusXcanR (Figure A.12) shows features that are
similar to Figure A.11 among the genes and variants at the locus. However, it more clearly
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Figure A.12: Example of LocusXanR’s network visualization.
depicts the connections between genes and variants, as well as the sharing of model variants
across genes. While the network visualization does not allow for easy interpretation of rela-
tive p-values, it does emphasize differences in predictive model weights (depicted by the line
thickness).
These are just two examples of the many features that the LocusXcanR application has
to offer. An example of the R shiny application used on a real data analysis (i.e. results from
TWAS and GWAS in GERA) is available in the R script R/example/example script.R
for your perusal.
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A.7 Publishing Your R Shiny Application
R Shiny applications may be shared via several different formats. Shiny applications
are fundamentally a web page, which subsequently allows them to be shared over the web.
Essentially, in order for the application to be shared over the web, you must arrange to replace
your own computer, which shares your app locally, with a web server that can share your app
over the cloud.
Files must be saved in a standardized format and directory structure in order for any
Shiny server to build your app. Once your app is appropriately packaged for a Shiny server,
RStudio recommends starting by launching your app on shinyapps.io. Shinyapps.io is a ser-
vice run by RStudio that allows you to share your apps online; the free server is built by
RStudio and is easy to use, secure, and scalable to multiple users.
For additional details and recommendations about publishing your application online, see
RStudio’s R Shiny tutorial: https://vimeo.com/rstudioinc/review/131218530/212d8a5a7a/
A.8 Frequently Asked Questions
Where can I learn more about getting started with R Shiny?
RStudio’s R Shiny video tutorials provide a great beginner’s guide to the R Shiny frame-
work: https://shiny.rstudio.com/tutorial/. Links to more advanced Shiny topics are available
from this web page as well.
What can I include in my header details?
The head details parameter is a character string parameter which may include sim-
ple text characters and/or HTML formatting commands. For example, simple text characters
may include the following:
head details = “All genomic positions are from GRCh37. TWAS results for 10
traits are presented in the figures and tables below.”
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HTML commands for formatting may be included as in the following example, with
HTML characters surrounded by quotes:
head details = “All genomic positions are from GRCh37. ăpą TWAS results for
10 traits are presented in the figures and tables below. Traits and trait categories
are listed and defined as follows:ăpąăuląălią Platelet count (PLT) ă/liąălią
Red blood cell indices (RBC): red blood cell count (RBC), hematocrit (HCT),
hemoglobin (HGB), mean corpuscular volume (MCV), and red cell distribution
width (RDW) ă/liąăliąWhite blood cell indices (WBC): white blood cell
count (WBC), monocyte (MONO), neutrophil (NEUTRO), and lymphocyte
(LYMPH) ă/liąă/ulą”
What can I include in my method details?
Similar to head details, the method details parameter is a character string pa-
rameter which may include simple text characters and/or HTML formatting commands. Addi-
tionally, method details may include R shiny functions as follows.
For example, the R code presented in Figure A.13 could be saved in a script called
methods.R. Then load your methods.R script into your working script, using for ex-
ample:
method <- source("methods.R").
Finally, use the method variable as the value of the method details parameter within
the LocusXcanR function, as in:
LocusXcanR(method details = method)
For a more detailed example of this procedure, see the example script.R script as
well as the methods.R script in R/example/.
Does the order of the column names in any of the datasets matter?
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Figure A.13: Example of an R shiny method details script methods.R.
The order of the column names does not matter. However, the names of the columns in
your data must match the column names (required or optional) listed for each dataset in the
Data Pre-processing sections. Any additional variables included in your datasets which do not
match those listed in the Data Pre-processing sections will also be printed in the data tables
within the shiny application, if applicable.
Is the methods.R example file necessary for the shiny app?
The methods.R script is not required for the application. If you do not give anything to
the method details parameter then it defaults to method details="".
What is the difference between gwas sentinel.txt and known gwas.txt example
files?
The gwas sentinel.txt example data file contains the data that are loaded into
the known variants parameter. These data will represent your list of known GWAS
sentinel variants from, for example, the latest GWAS analysis on your phenotype of in-
terest. The known gwas.txt example file contains the analytic cohort GWAS p-values
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that correspond to the known variants from the latest GWAS analysis. So the variants in the
known gwas.txt file match the variants in the gwas sentinel.txt file (where there
are matches), but the p-value in the known gwas.txt file should come from GWAS in
your analytic cohort.
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APPENDIX B: ADDITIONAL DETAILS FOR CHAPTER 4
This appendix contains additional details for Chapter 4.
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Table B.1: ARIC association summary statistics using observed metabolites or predicted metabolites. Associations are limited to those
that are statistically significant with observed metabolites, are nominally significant with predicted metabolites, and have an elastic net
model R2 ą 0.05. None of these associations have the same direction of effect, and the estimates themselves differ wildly when
comparing observed estimates to predicted estimates.
Observed metabolites Predicted metabolites
ancestry phenotype metabolite Estimate SE p-value Estimate SE p-value
AA WBC bilirubinEE -0.11 0.025 9.36E-06 0.42 0.203 4.00E-02
AA WBC hydroxybutyrate2 0.10 0.024 1.97E-05 -0.63 0.309 4.18E-02
EA WBC aminooctanoate -0.17 0.026 1.92E-10 0.10 0.051 4.25E-02
EA hemoglobin arachidonate204n6 0.12 0.026 7.15E-06 -0.11 0.040 7.94E-03
EA neutrophil bilirubinEE -0.15 0.028 8.66E-08 0.16 0.072 2.50E-02
EA hematocrit hydroxyphenyllactate 0.12 0.027 8.77E-06 -0.15 0.064 1.98E-02
EA hemoglobin hydroxyphenyllactate 0.12 0.027 8.92E-06 -0.13 0.064 4.71E-02
EA neutrophil indolepropionate -0.15 0.031 2.82E-06 0.49 0.245 4.50E-02
EA neutrophil mannose 0.21 0.038 2.84E-08 -0.18 0.085 3.61E-02
EA WBC mannose 0.23 0.030 1.58E-13 -0.17 0.072 1.80E-02
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Wieland, T., Greger, L., Van Iterson, M., Almlöf, J., Ribeca, P., Pulyakhina, I., Esser, D.,
Giger, T., Tikhonov, A., Sultan, M., Bertier, G., Macarthur, D. G., Lek, M., Lizano, E.,
Buermans, H. P. J., Padioleau, I., Schwarzmayr, T., Karlberg, O., Ongen, H., Kilpinen,
H., Beltran, S., Gut, M., Kahlem, K., Amstislavskiy, V., Stegle, O., Pirinen, M., Mont-
gomery, S. B., Donnelly, P., Lehrach, H., Schreiber, S., Sudbrak, R., Ngel Carracedo,
A. ., Antonarakis, S. E., Häsler, R., Syvänen, A.-C., Van Ommen, G.-J., Brazma, A.,
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tenmüller, G., Köttgen, A., Kronenberg, F., Mangino, M., Meisinger, C., Meitinger, T.,
Mewes, H.-W., Milburn, M. V., Prehn, C., Raffler, J., Ried, J. S., Römisch-Margl, W.,
Samani, N. J., Small, K. S., -Erich Wichmann, H., Zhai, G., Illig, T., Spector, T. D.,
Adamski, J., Soranzo, N., and Gieger, C. (2011). Human metabolic individuality in
biomedical and pharmaceutical research. Nature, 477(7362), 54–60.
Sun, B. B., Maranville, J. C., Peters, J. E., Stacey, D., Staley, J. R., Blackshaw, J., Burgess,
S., Jiang, T., Paige, E., Surendran, P., Oliver-Williams, C., Kamat, M. A., Prins, B. P.,
Wilcox, S. K., Zimmerman, E. S., Chi, A., Bansal, N., Spain, S. L., Wood, A. M., Mor-
rell, N. W., Bradley, J. R., Janjic, N., Roberts, D. J., Ouwehand, W. H., Todd, J. A., So-
ranzo, N., Suhre, K., Paul, D. S., Fox, C. S., Plenge, R. M., Danesh, J., Runz, H., and
Butterworth, A. S. (2018). Genomic atlas of the human plasma proteome. Nature,
558(7708), 73–79.
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